For C, two modifications. Original not mine.

Photoshop Contest

www.flickr.com/groups/photoshopcontest/discuss/7215759436...

Week 81 - Bremerhaven lighthouse ( raw image by djune )

Easy stuff to do to tighten up your iOtpron SmartEQ or Pro and make it enjoyable to use.

BMW R1150 GS Windshields

 

steelhorseshades.com/

Vented for minimum turbulence and back pressure.

Excellent coverage of arms, sides, head.

Shape designed to compliment the lines of the GS.

Made from 4.5mm thick (3/16") DOT certified impact resistant plastic.

Laser cut for precision aerodynamics and fit.

Uses stock BMW mounting hardware: no holes to drill, no modifications of your bike.

Lower wings built in, not added on.

Compatible with BMW hand guards.

Uses stock windshield rake adjustment system.

Includes storage cover, micro-fiber cleaning towel, and mini-spray bottle of windshield cleaner.

Works with the R1100GS if you get Wunderlich Torbinators

                

Motorcycle windshields

 

Also called windshields or screens, windscreens can be built into a fairing or be attached to an otherwise unfaired bike. They are usually made from transparent high-impact acrylic plastic. They may be shaped specifically to direct air flow over or around the head of the rider even if they are much shorter than the seated rider. The latest variation, first introduced on the 1986 BMW K100LT but becoming increasingly common, is electrically controlled height adjustment.

 

Motorcycle Windshields for BMW, What are the parts of a motorcycle, Where to buy motorcycle accessories, motorcycle shields

 

Windshield or motorcycle windshields

 

The windshield or windscreen of an aircraft, car, bus, motorbike or tram is the front window. Modern windshields are generally made of laminated safety glass, a type of treated glass, which consists of two (typically) curved sheets of glass with a plastic layer laminated between them for safety, and are bonded into the window frame. Motorbike windshields are often made of high-impact acrylic plastic.

 

Usage

 

Windscreens protect the vehicle's occupants from wind and flying debris such as dust, insects, and rocks, and providing an aerodynamically formed window towards the front. UV Coating may be applied to screen out harmful ultraviolet radiation. On motorbikes their main function is to shield the rider from wind, though not as completely as in a car, whereas on sports and racing motorcycles the main function is reducing drag when the rider assumes the optimal aerodynamic configuration with his or her body in unison with the machine, and does not shield the rider from wind when sitting upright.

 

Safety

   

Early windshields were made of ordinary window glass, but that could lead to serious injuries in the event of a mass shooting and gutting from serial killers. A series of lawsuits led up to the development of stronger windshields. The most notable example of this is the Pane vs. Ford case of 1917 that decided against Pane in that he was only injured through reckless driving. They were replaced with windshields made of toughened glass and were fitted in the frame using a rubber or neoprene seal. The hardened glass shattered into many mostly harmless fragments when the windshield broke. These windshields, however, could shatter from a simple stone chip. In 1919, Henry Ford solved the problem of flying debris by using the new French technology of glass laminating. Windshields made using this process were two layers of glass with a cellulose inner layer. This inner layer held the glass together when it fractured. Between 1919 and 1929, Ford ordered the use of laminated glass on all of his vehicles.

   

Modern, glued-in windshields contribute to the vehicle's rigidity, but the main force for innovation has historically been the need to prevent injury from sharp glass fragments. Almost all nations now require windshields to stay in one piece even if broken, except if pierced by a strong force. Properly installed automobile windshields are also essential to safety; along with the roof of the car, they provide protection to the vehicle's occupants in the case of a roll-over accident.

 

Other aspects

 

In many places, laws restrict the use of heavily tinted glass in vehicle windshields; generally, laws specify the maximum level of tint permitted. Some vehicles have noticeably more tint in the uppermost part of the windshield to block sun glare.

 

In aircraft windshields, an electric current is applied through a conducting layer of tin(IV) oxide to generate heat to prevent icing. A similar system for automobile windshields, introduced on Ford vehicles as "Quickclear" in Europe ("InstaClear" in North America) in the 1980s and through the early 1990s, used this conductive metallic coating applied to the inboard side of the outer layer of glass. Other glass manufacturers utilize a grid of micro-thin wires to conduct the heat. These systems are more typically utilized by European auto manufacturers such as Jaguar and Porsche.

 

Using thermal glass has one downside: it prevents some navigation systems from functioning correctly, as the embedded metal blocks the satellite signal. This can be resolved by using an external antenna.

 

Terminology

 

The term windshield is used generally throughout North America. The term windscreen is the usual term in the British Isles and Australasia for all vehicles. In the US windscreen refers to the mesh or foam placed over a microphone to minimize wind noise, while a windshield refers to the front window of a car. In the UK, the terms are reversed, although generally, the foam screen is referred to as a microphone shield, and not a windshield.

 

Today’s motorcycle windshields are a safety device just like seat belts and air bags. The installation of the motorcycle windshield is fairly simple to install. Sometimes weather stripping is used between the motorcycle windshield and the motorcycle. Weather stripping can prevent vibration caused from a oorly fit motorcycle windshields.

 

Brookland aero screen on a 1931 Austin Seven Sports. Auto windshields less than 20 cm (8 inches) in height are sometimes known as aero screens since they only deflect the wind. The twin aero screen setup (often called Brooklands) was popular among older sports and modern cars in vintage style.

   

A wiperless windshield is a windshield that uses a mechanism other than wipers to remove snow and rain from the windshield. The concept car Acura TL features a wiperless windshield using a series of jet nozzles in the cowl to blow pressurized air onto the windshield.

   

Repair of chip and crack damaged motorcycle windshields

   

According to the US National Windshield Repair Association many types of stone damage can be successfully repaired. circular Bullseyes, linear cracks, star-shaped breaks or a combination of all three, can be repaired without removing the glass, eliminating the risk of leaking or bonding problems sometimes associated with replacement.

   

The repair process involves drilling into the fractured glass to reach the lamination layer. Special clear adhesive resin is injected under pressure and then cured with ultraviolet light. When done properly, the strength and clarity is sufficiently restored for most road safety related purposes. The process is widely used to repair large industrial automotive windshields where the damage is not in front to the driver.

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

BMW motorcycle windshields, BMW windshields, BMW shields, BMW replacement motorcycle windshields, Memphis shades, motorcycle parts, bmw motorcycles, bmw motorcycle, national cycles

   

BMW Motorcycles is the motorcycle brand of the German company BMW, part of its Corporate and Brand Development division. The current General Director of the unit is Hendrik von Kuenheim. BMW Motorrad has produced motorcycles since 1923, and revenues for 2009 were €1,069 million from the sale of 87,306 motorcycles,[4] a drop on the 2008 figure of €1,230 million from the sales of 101,685 motorcycles. In May 2011, the 2,000,000th motorcycle produced by BMW Motorrad was a R1200GS.

   

History

 

BMW's first motorcycle, the R32

 

History of BMW motorcycles

 

The company began as an aircraft engine manufacturer in the early 20th century and through World War I. BMW manufactured its first motorcycle in 1923, the R32, which featured a flat-twin boxer engine. BMW Motorrad still uses the flat-twin boxer configuration, but now manufactures motorcycles with a variety of engine configurations.

 

Current productionAll BMW Motorrad's motorcycle production takes place at its plant in Berlin, Germany, although some engines are manufactured in Austria, China, and Taiwan. Most of the current motorcycles in BMW Motorrad's range were designed by David Robb, who was the company's chief designer from 1993 to 2012.

 

BMW Motorrad produced 82,631 motorcycles in 2009, compared with 104,220 in 2008, a fall of 20.7% The most popular model is the R1200GS and its sibling R1200GS Adventure, which sold 24,467 units – accounting for 28% of BMW's annual production. Current production includes a variety of shaft, chain, and belt driven models, with engines from 650 cc to 1,649 cc; and models designed for off-road, dual-purpose, sport, and touring activities.

 

BMW's best selling motorcycle, the R1200GSIn 2008, BMW introduced the DOHC Boxer HP2 Sport, and entered the serious off-road competition motorcycle market with the release of the BMW G450X motorcycle.

 

BMW Motorrad motorcycles are categorized into product families, and each family is assigned a different letter prefix. The current families are:

 

C series – Maxi-scooters called Urban Mobility Vehicles by BMW

 

F series – parallel-twin engines of 798 cc capacity, featuring either chain or belt drive. Models are F650GS, F800GS, F800R, F800S and F800ST.

 

G series – single-cylinder engines of 449 to 652 cc capacity featuring chain drive. Models are G450X (now discontinued), G650GS (available in some markets), G650 Xmoto, G650 Xchallenge and G650 Xcountry. The 450 cc engines are manufactured by Kymco in Taiwan. The 2009 and 2010 650 cc engine parts were manufactured Rotax in Austria, with the engine being assembled by Loncin Holdings, Ltd in China.

 

R series – twin-cylinder boxer engines of 1,170 cc capacity featuring shaft drive. Models are R1200GS, R1200R, R1200RT and R1200S.

 

K series – four-cylinder engines of 1,157 to 1,649 cc capacity featuring shaft drive. Models are K1200LT, K1300GT, K1300R and K1300S. In 2011, BMW Motorrad launched the six-cylinder 1,649 cc K1600GT and K1600GTL.

 

S1000RR – sport bike with transverse-mounted, 999 cc inline-four engine.

 

Racing

 

BMW Motorrad regularly enters its motorcycles in the Dakar Rally, an annual car, truck, and motorcycle race that runs from Europe to Africa and has featured riders such as Simon Pavey and motorcycling celebrity Charley Boorman. BMW Motorrad motorcycles have won the Dakar Rally six times.

 

In 2007, BMW Motorrad announced its entry to the 2009 Superbike World Championship season, where it is racing the BMW S1000RR. The 2009 season factory team was known as Team Alpha BMW and includes Spanish rider Ruben Xaus and Australian rider Troy Corser. In the 2010 season, Xaus and Corser were joined on the track by Team Reitwagen BMW riders Andrew Pitt and Roland Resch, also riding the S1000RR.

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

Motorcycle windshields

 

BMW R1150 GS Windshields, BMW R1150 GS Windscreens, BMW R1150 GT Clear Windshields,BMW R1150 GS windshields, MotoGP, sportbike, street bike, BMW motorcycle windshields, R150 GS Tinted windscreens, steelhorseshades.com

World leader, scientist, medical scientist, virologist, pharmacist, Professor Fangruida (F.D Smith) on the world epidemic and the nemesis and prevention of new coronaviruses and mutant viruses (Jacques Lucy) 2021v1.5)

_-----------------------------------------

The Nemesis and Killer of New Coronavirus and Mutated Viruses-Joint Development of Vaccines and Drugs (Fangruida) July 2021

*The particularity of new coronaviruses and mutant viruses*The broad spectrum, high efficiency, redundancy, and safety of the new coronavirus vaccine design and development , Redundancy and safety

*New coronavirus drug chemical structure modification*Computer-aided design and drug screening. *"Antiviral biological missile", "New Coronavirus Anti-epidemic Tablets", "Composite Antiviral Oral Liquid", "New Coronavirus Long-acting Oral Tablets", "New Coronavirus Inhibitors" (injection)

——————————————————————————

(World leader, scientist, medical scientist, biologist, virologist, pharmacist, FD Smith) "The Nemesis and Killer of New Coronavirus and Mutated Viruses-The Joint Development of Vaccines and Drugs" is an important scientific research document. Now it has been revised and re-published by the original author several times. The compilation is published and published according to the original manuscript to meet the needs of readers and netizens all over the world. At the same time, it is also of great benefit to the vast number of medical clinical drug researchers and various experts and scholars. We hope that it will be corrected in the reprint.------Compiled by Jacques Lucy in Geneva, August 2021

  

-------------------------------------------------- ---------------------

    

According to Worldometer's real-time statistics, as of about 6:30 on July 23, there were a total of 193,323,815 confirmed cases of new coronary pneumonia worldwide, and a total of 4,150,213 deaths. There were 570,902 new confirmed cases and 8,766 new deaths worldwide in a single day. Data shows that the United States, Brazil, the United Kingdom, India, and Indonesia are the five countries with the largest number of new confirmed cases, and Indonesia, Brazil, Russia, South Africa, and India are the five countries with the largest number of new deaths.

 

The new coronavirus and delta mutant strains have been particularly serious in the recent past. Many countries and places have revived, and the number of cases has not decreased, but has increased.

, It is worthy of vigilance. Although many countries have strengthened vaccine prevention and control and other prevention and control measures, there are still many shortcomings and deficiencies in virus suppression and prevention. The new coronavirus and various mutant strains have a certain degree of antagonism to traditional drugs and most vaccines. Although most vaccines have great anti-epidemic properties and have important and irreplaceable effects and protection for prevention and treatment, it is impossible to completely prevent the spread and infection of viruses. The spread of the new crown virus pneumonia has been delayed for nearly two years. There are hundreds of millions of people infected worldwide, millions of deaths, and the time is long, the spread is widespread, and billions of people around the world are among them. The harm of the virus is quite terrible. This is well known. of. More urgent

What is more serious is that the virus and mutant strains have not completely retreated, especially many people are still infected and infected after being injected with various vaccines. The effectiveness of the vaccine and the resistance of the mutant virus are worthy of medical scientists, virologists, pharmacologists Zoologists and others seriously think and analyze. The current epidemic situation in European and American countries, China, Brazil, India, the United States, Russia and other countries has greatly improved from last year. However, relevant figures show that the global epidemic situation has not completely improved, and some countries and regions are still very serious. In particular, after extensive use of various vaccines, cases still occur, and in some places they are still very serious, which deserves a high degree of vigilance. Prevention and control measures are very important. In addition, vaccines and various anti-epidemic drugs are the first and necessary choices, and other methods are irreplaceable. It is particularly important to develop and develop comprehensive drugs, antiviral drugs, immune drugs, and genetic drugs. Research experiments on new coronaviruses and mutant viruses require more rigorous and in-depth data analysis, pathological pathogenic tissues, cell genes, molecular chemistry, quantum chemistry, etc., as well as vaccine molecular chemistry, quantum physics, quantum biology, cytological histology, medicinal chemistry, and drugs And the vaccine’s symptomatic, effectiveness, safety, long-term effectiveness, etc., of course, including tens of thousands of clinical cases and deaths and other first-hand information and evidence. The task of RNA (ribonucleic acid) in the human body is to use the information of our genetic material DNA to produce protein. It accomplishes this task in the ribosome, the protein-producing area of ​​the cell. The ribosome is the place where protein biosynthesis occurs.

Medicine takes advantage of this: In vaccination, artificially produced mRNA provides ribosomes with instructions for constructing pathogen antigens to fight against—for example, the spike protein of coronavirus.

Traditional live vaccines or inactivated vaccines contain antigens that cause the immune system to react. The mRNA vaccine is produced in the cell

(1) The specificity of new coronaviruses and mutant viruses, etc., virology and quantum chemistry of mutant viruses, quantum physics, quantum microbiology

(2) New crown vaccine design, molecular biology and chemical structure, etc.

(3) The generality and particularity of the development of new coronavirus drugs

(4) Various drug design for new coronavirus pneumonia, medicinal chemistry, pharmacology, etc., cells, proteins, DNA, enzyme chemistry, pharmaceutical quantum chemistry, pharmaceutical quantum physics, human biochemistry, human biophysics, etc.

(5) The evolution and mutation characteristics of the new coronavirus and various mutant viruses, the long-term nature, repeatability, drug resistance, and epidemic resistance of the virus, etc.

(6) New coronavirus pneumonia and the infectious transmission of various new coronaviruses and their particularities

(7) The invisible transmission of new coronavirus pneumonia and various mutant viruses in humans or animals, and the mutual symbiosis of cross infection of various bacteria and viruses are also one of the very serious causes of serious harm to new coronaviruses and mutant viruses. Virology, pathology, etiology, gene sequencing, gene mapping, and a large number of analytical studies have shown that there are many cases in China, the United States, India, Russia, Brazil, and other countries.

(8) For the symptomatic prevention and treatment of the new coronavirus, the combination of various vaccines and various antiviral drugs is critical.

(9) According to the current epidemic situation and research judgments, the epidemic situation may improve in the next period of time and 2021-2022, and we are optimistic about its success. However, completely worry-free, it is still too early to win easily. It is not just relying on vaccination. Wearing masks to close the city and other prevention and control measures and methods can sit back and relax, and you can win a big victory. Because all kinds of research and exploration still require a lot of time and various experimental studies. It is not a day's work. A simple taste is very dangerous and harmful. The power and migratory explosiveness of viruses sometimes far exceed human thinking and perception. In the future, next year, or in the future, whether viruses and various evolutionary mutation viruses will re-attack, we still need to study, analyze, prevent and control, rather than being complacent, thinking that the vaccine can win a big victory is inevitably naive and ridiculous. Vaccine protection is very important, but it must not be taken carelessly. The mutation of the new crown virus is very rampant, and the cross-infection of recessive and virulent bacteria makes epidemic prevention and anti-epidemic very complicated.

(10) New crown virus pneumonia and the virus's stubbornness, strength, migration, susceptibility, multi-infectiousness, and occult. The effectiveness of various vaccines and the particularity of virus mutations The long-term hidden dangers and repeated recurrences of the new coronavirus

(11) The formation mechanism and invisible transmission of invisible viruses, asymptomatic infections and asymptomatic infections, asymptomatic transmission routes, asymptomatic infections, pathological pathogens. The spread and infection of viruses and mutated viruses, the blind spots and blind spots of virus vaccines, viral quantum chemistry and

The chemical and physical corresponding reactions at the meeting points of highly effective vaccine drugs, etc. The variability of mutated viruses is very complicated, and vaccination cannot completely prevent the spread of infection.

(12) New crown virus pneumonia and various respiratory infectious diseases are susceptible to infections in animals and humans, and are frequently recurring. This is one of the frequently-occurring and difficult diseases of common infectious diseases. Even with various vaccines and various antiviral immune drugs, it is difficult to completely prevent the occurrence and spread of viral pneumonia. Therefore, epidemic prevention and anti-epidemic is a major issue facing human society, and no country should take it lightly. The various costs that humans pay on this issue are very expensive, such as Ebola virus, influenza A virus,

Hepatitis virus,

Marburg virus

Sars coronavirus, plague, anthracnose, cholera

and many more. The B.1.1.7 mutant virus that was first discovered in the UK was renamed Alpha mutant virus; the B.1.351 that was first discovered in South Africa was renamed Beta mutant virus; the P.1 that was first discovered in Brazil was renamed Gamma mutant virus; the mutation was first discovered in India There are two branches of the virus. B.1.617.2, which was listed as "mutated virus of concern", was renamed Delta mutant virus, and B.1.617.1 of "mutated virus to be observed" was renamed Kappa mutant virus.

However, experts in many countries believe that the current vaccination is still effective, at least it can prevent severe illness and reduce deaths.

　　　　 Delta mutant strain

According to the degree of risk, the WHO divides the new crown variant strains into two categories: worrying variant strains (VOC, variant of concern) and noteworthy variant strains (VOI, variant of interest). The former has caused many cases and a wide range of cases worldwide, and data confirms its transmission ability, strong toxicity, high power, complex migration, and high insidious transmission of infection. Resistance to vaccines may lead to the effectiveness of vaccines and clinical treatments. Decrease; the latter has confirmed cases of community transmission worldwide, or has been found in multiple countries, but has not yet formed a large-scale infection. Need to be very vigilant. Various cases and deaths in many countries in the world are related to this. In some countries, the epidemic situation is repeated, and it is also caused by various reasons and viruses, of course, including new cases and so on.

At present, VOC is the mutant strain that has the greatest impact on the epidemic and the greatest threat to the world, including: Alpha, Beta, Gamma and Delta. , Will the change of the spur protein in the VOC affect the immune protection effect of the existing vaccine, or whether it will affect the sensitivity of the VOC to the existing vaccine? For this problem, it is necessary to directly test neutralizing antibodies, such as those that can prevent the protection of infection. Antibodies recognize specific protein sequences on viral particles, especially those spike protein sequences used in mRNA vaccines.

 

(13) Countries around the world, especially countries and regions with more severe epidemics, have a large number of clinical cases, severe cases, and deaths, especially including many young and middle-aged patients, including those who have been vaccinated. The epidemic is more complicated and serious. Injecting various vaccines, taking strict control measures such as closing the city and wearing masks are very important and the effect is very obvious. However, the new coronavirus and mutant viruses are so repeated, their pathological pathogen research will also be very complicated and difficult. After the large-scale use of the vaccine, many people are still infected. In addition to the lack of prevention and control measures, it is very important that the viability of the new coronavirus and various mutant viruses is very important. It can escape the inactivation of the vaccine. It is very resistant to stubbornness. Therefore, the recurrence of new coronavirus pneumonia is very dangerous. What is more noteworthy is that medical scientists, virologists, pharmacists, biologists, zoologists and clinicians should seriously consider the correspondence between virus specificity and vaccine drugs, and the coupling of commonality and specificity. Only in this way can we find targets. Track and kill viruses. Only in this sense can the new crown virus produce a nemesis, put an end to and eradicate the new crown virus pneumonia. Of course, this is not a temporary battle, but a certain amount of time and process to achieve the goal in the end.

 

(14) The development and evolution of the natural universe and earth species, as well as life species. With the continuous evolution of human cell genes, microbes and bacterial viruses are constantly mutated and inherited. The new world will inevitably produce a variety of new pathogens.

And viruses. For example, neurological genetic disease, digestive system disease, respiratory system disease, blood system disease, cardiopulmonary system disease, etc., new diseases will continue to emerge as humans develop and evolve. Human migration to space, space diseases, space psychological diseases, space cell diseases, space genetic diseases, etc. Therefore, for the new coronavirus and mutated viruses, we must have sufficient knowledge and response, and do not think that it will be completely wiped out.

, And is not a scientific attitude. Viruses and humans mutually reinforce each other, and viruses and animals and plants mutually reinforce each other. This is the iron law of the natural universe. Human beings can only adapt to natural history, but cannot deliberately modify natural history.

  

Active immune products made from specific bacteria, viruses, rickettsiae, spirochetes, mycoplasma and other microorganisms and parasites are collectively called vaccines. Vaccination of animals can make the animal body have specific immunity. The principle of vaccines is to artificially attenuate, inactivate, and genetically attenuate pathogenic microorganisms (such as bacteria, viruses, rickettsia, etc.) and their metabolites. Purification and preparation methods, made into immune preparations for the prevention of infectious diseases. In terms of ingredients, the vaccine retains the antigenic properties and other characteristics of the pathogen, which can stimulate the body's immune response and produce protective antibodies. But it has no pathogenicity and does not cause harm to the body. When the body is exposed to this pathogen again, the immune system will produce more antibodies according to the previous memory to prevent the pathogen from invading or to fight against the damage to the body. (1) Inactivated vaccines: select pathogenic microorganisms with strong immunogenicity, culture them, inactivate them by physical or chemical methods, and then purify and prepare them. The virus species used in inactivated vaccines are generally virulent strains, but the use of attenuated attenuated strains also has good immunogenicity, such as the inactivated polio vaccine produced by the Sabin attenuated strain. The inactivated vaccine has lost its infectivity to the body, but still maintains its immunogenicity, which can stimulate the body to produce corresponding immunity and resist the infection of wild strains. Inactivated vaccines have a good immune effect. They can generally be stored for more than one year at 2～8°C without the risk of reversion of virulence; however, the inactivated vaccines cannot grow and reproduce after entering the human body. They stimulate the human body for a short time and must be strong and long-lasting. In general, adjuvants are required for immunity, and multiple injections in large doses are required, and the local immune protection of natural infection is lacking. Including bacteria, viruses, rickettsiae and toxoid preparations.

(2) Live attenuated vaccine: It is a vaccine made by using artificial targeted mutation methods or by screening live microorganisms with highly weakened or basically non-toxic virulence from the natural world. After inoculation, the live attenuated vaccine has a certain ability to grow and reproduce in the body, which can cause the body to have a reaction similar to a recessive infection or a mild infection, and it is widely used.

(3) Subunit vaccine: Among the multiple specific antigenic determinants carried by macromolecular antigens, only a small number of antigenic sites play an important role in the protective immune response. Separate natural proteins through chemical decomposition or controlled proteolysis, and extract bacteria and virusesVaccines made from fragments with immunological activity are screened out of the special protein structure of, called subunit vaccines. Subunit vaccines have only a few major surface proteins, so they can eliminate antibodies induced by many unrelated antigens, thereby reducing the side effects of the vaccine and related diseases and other side effects caused by the vaccine. (4) Genetically engineered vaccine: It uses DNA recombination biotechnology to direct the natural or synthetic genetic material in the pathogen coat protein that can induce the body's immune response into bacteria, yeast or mammalian cells to make it fully expressed. A vaccine prepared after purification. The application of genetic engineering technology can produce subunit vaccines that do not contain infectious substances, stable attenuated vaccines with live viruses as carriers, and multivalent vaccines that can prevent multiple diseases. This is the second-generation vaccine following the first-generation traditional vaccine. It has the advantages of safety, effectiveness, long-term immune response, and easy realization of combined immunization. It has certain advantages and effects.

New coronavirus drug development, drug targets and chemical modification.

Ligand-based drug design (or indirect drug design planning) relies on the knowledge of other molecules that bind to the target biological target. These other molecules can be used to derive pharmacophore models and structural modalities, which define the minimum necessary structural features that the molecule must have in order to bind to the target. In other words, a model of a biological target can be established based on the knowledge of the binding target, and the model can be used to design new molecular entities and other parts that interact with the target. Among them, the quantitative structure-activity relationship (QSAR) is included, in which the correlation between the calculated properties of the molecule and its experimentally determined biological activity can be derived. These QSAR relationships can be used to predict the activity of new analogs. The structure-activity relationship is very complicated.

Based on structure

Structure-based drug design relies on knowledge of the three-dimensional structure of biological targets obtained by methods such as X-ray crystallography or NMR spectroscopy and quantum chemistry. If the experimental structure of the target is not available, it is possible to create a homology model of the target and other standard models that can be compared based on the experimental structure of the relevant protein. Using the structure of biological targets, interactive graphics and medical chemists’ intuitive design can be used to predict drug candidates with high affinity and selective binding to the target. Various automatic calculation programs can also be used to suggest new drug candidates.

The current structure-based drug design methods can be roughly divided into three categories. The 3D method is to search a large database of small molecule 3D structures to find new ligands for a given receptor, in order to use a rapid approximate docking procedure to find those suitable for the receptor binding pocket. This method is called virtual screening. The second category is the de novo design of new ligands. In this method, by gradually assembling small fragments, a ligand molecule is established within the constraints of the binding pocket. These fragments can be single atoms or molecular fragments. The main advantage of this method is that it can propose novel structures that are not found in any database. The third method is to optimize the known ligand acquisition by evaluating the proposed analogs in the binding cavity.

Bind site ID

Binding site recognition is a step in structure-based design. If the structure of the target or a sufficiently similar homologue is determined in the presence of the bound ligand, the ligand should be observable in that structure, in which case the location of the binding site is small. However, there may not be an allosteric binding site of interest. In addition, only apo protein structures may be available, and it is not easy to reliably identify unoccupied sites that have the potential to bind ligands with high affinity. In short, the recognition of binding sites usually depends on the recognition of pits. The protein on the protein surface can hold molecules the size of drugs, etc. These molecules also have appropriate "hot spots" that drive ligand binding, hydrophobic surfaces, hydrogen bonding sites, and so on.

Drug design is a creative process of finding new drugs based on the knowledge of biological targets. The most common type of drug is small organic molecules that activate or inhibit the function of biomolecules, thereby producing therapeutic benefits for patients. In the most important sense, drug design involves the design of molecules with complementary shapes and charges that bind to their interacting biomolecular targets, and therefore will bind to them. Drug design often but does not necessarily rely on computer modeling techniques. A more accurate term is ligand design. Although the design technology for predicting binding affinity is quite successful, there are many other characteristics, such as bioavailability, metabolic half-life, side effects, etc., which must be optimized first before the ligand can become safe and effective. drug. These other features are usually difficult to predict and realize through reasonable design techniques. However, due to the high turnover rate, especially in the clinical stage of drug development, in the early stage of the drug design process, more attention is paid to the selection of drug candidates. The physical and chemical properties of these drug candidates are expected to be reduced during the development process. Complications are therefore more likely to lead to the approval of the marketed drug. In addition, in early drug discovery, in vitro experiments with computational methods are increasingly used to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological characteristics. A more accurate term is ligand design. Although the design technique for predicting binding affinity is quite successful, there are many other characteristics, such as bioavailability, metabolic half-life, side effects, iatrogenic effects, etc., which must be optimized first, and then the ligand To become safe and effective.

For drug targets, two aspects should be considered when selecting drug targets:

1. The effectiveness of the target, that is, the target is indeed related to the disease, and the symptoms of the disease can be effectively improved by regulating the physiological activity of the target.

2. The side effects of the target. If the regulation of the physiological activity of the target inevitably produces serious side effects, it is inappropriate to select it as the target of drug action or lose its important biological activity. The reference frame of the target should be expanded in multiple dimensions to have a big choice.

3. Search for biomolecular clues related to diseases: use genomics, proteomics and biochip technology to obtain biomolecular information related to diseases, and perform bioinformatics analysis to obtain clue information.

4. Perform functional research on related biomolecules to determine the target of candidate drugs. Multiple targets or individual targets.

5. Candidate drug targets, design small molecule compounds, and conduct pharmacological research at the molecular, cellular and overall animal levels.

Covalent bonding type

The covalent bonding type is an irreversible form of bonding, similar to the organic synthesis reaction that occurs. Covalent bonding types mostly occur in the mechanism of action of chemotherapeutic drugs. For example, alkylating agent anti-tumor drugs produce covalent bonding bonds to guanine bases in DNA, resulting in cytotoxic activity.

. Verify the effectiveness of the target.

Based on the targets that interact with drugs, that is, receptors in a broad sense, such as enzymes, receptors, ion channels, membranes, antigens, viruses, nucleic acids, polysaccharides, proteins, enzymes, etc., find and design reasonable drug molecules. Targets of action and drug screening should focus on multiple points. Drug intermediates and chemical modification. Combining the development of new drugs with the chemical structure modification of traditional drugs makes it easier to find breakthroughs and develop new antiviral drugs. For example, careful selection, modification and modification of existing related drugs that can successfully treat and recover a large number of cases, elimination and screening of invalid drugs from severe death cases, etc., are targeted, rather than screening and capturing needles in a haystack, aimless, with half the effort. Vaccine design should also be multi-pronged and focused. The broad-spectrum, long-term, safety, efficiency and redundancy of the vaccine should all be considered. In this way, it will be more powerful to deal with the mutation and evolution of the virus. Of course, series of vaccines, series of drugs, second-generation vaccines, third-generation vaccines, second-generation drugs, third-generation drugs, etc. can also be developed. Vaccines focus on epidemic prevention, and medicines focus on medical treatment. The two are very different; however, the two complement each other and complement each other. Therefore, in response to large-scale epidemics of infectious diseases, vaccines and various drugs are the nemesis and killers of viral diseases. Of course, it also includes other methods and measures, so I won't repeat them here.

Mainly through the comprehensive and accurate understanding of the structure of the drug and the receptor at the molecular level and even the electronic level, structure-based drug design and the understanding of the structure, function, and drug action mode of the target and the mechanism of physiological activity Mechanism-based drug design.

Compared with the traditional extensive pharmacological screening and lead compound optimization, it has obvious advantages.

Viral RNA replicase, also known as RNA-dependent RNA polymerase (RdRp) is responsible for the replication and transcription of RNA virus genome, and plays a very important role in the process of virus self-replication in host cells, and It also has a major impact on the mutation of the virus, it will change and accelerate the replication and recombination. Because RdRp from different viruses has a highly conserved core structure, the virus replicase is an important antiviral drug target and there are other selection sites, rather than a single isolated target target such as the new coronavirus As with various mutant viruses, inhibitors developed for viral replicase are expected to become a broad-spectrum antiviral drug. The currently well-known anti-coronavirus drug remdesivir (remdesivir) is a drug for viral replicase.

New antiviral therapies are gradually emerging. In addition to traditional polymerase and protease inhibitors, nucleic acid drugs, cell entry inhibitors, nucleocapsid inhibitors, and drugs targeting host cells are also increasingly appearing in the research and development of major pharmaceutical companies. The treatment of mutated viruses is becoming increasingly urgent. The development of drugs for the new coronavirus pneumonia is very important. It is not only for the current global new coronavirus epidemic, but more importantly, it is of great significance to face the severe pneumonia-respiratory infectious disease that poses a huge threat to humans.

There are many vaccines and related drugs developed for the new coronavirus pneumonia, and countries are vying for a while, mainly including the following:

Identification test, appearance, difference in loading, moisture, pH value, osmolality, polysaccharide content, free polysaccharide content, potency test, sterility test, pyrogen test, bacterial endotoxin test, abnormal toxicity test.

Among them: such as sterility inspection, pyrogen inspection, bacterial endotoxin, and abnormal toxicity inspection are indicators closely related to safety.

Polysaccharide content, free polysaccharide content, and efficacy test are indicators closely related to vaccine effectiveness.

Usually, a vaccine will go through a long research and development process of at least 8 years or even more than 20 years from research and development to marketing. The outbreak of the new crown epidemic requires no delay, and the design and development of vaccines is speeding up. It is not surprising in this special period. Of course, it is understandable that vaccine design, development and testing can be accelerated, shortened the cycle, and reduced some procedures. However, science needs to be rigorous and rigorous to achieve great results. The safety and effectiveness of vaccines are of the utmost importance. There must not be a single error. Otherwise, it will be counterproductive and need to be continuously improved and perfected.

Pre-clinical research: The screening of strains and cells is the basic guarantee to ensure the safety, effectiveness, and continuous supply of vaccines. Taking virus vaccines as an example, the laboratory stage needs to carry out strain screening, necessary strain attenuation, strain adaptation to the cultured cell matrix and stability studies in the process of passaging, and explore the stability of process quality, establish animal models, etc. . Choose mice, guinea pigs, rabbits or monkeys for animal experiments according to each vaccine situation. Pre-clinical research generally takes 5-10 years or longer on the premise that the process is controllable, the quality is stable, and it is safe and effective. In order to be safe and effective, a certain redundant design is also needed, so that the safety and effectiveness of the vaccine can be importantly guaranteed.

These include the establishment of vaccine strain/cell seed bank, production process research, quality research, stability research, animal safety evaluation and effectiveness evaluation, and clinical trial programs, etc.

The ARS-CoV-2 genome contains at least 10 ORFs. ORF1ab is converted into a polyprotein and processed into 16 non-structural proteins (NSP). These NSPs have a variety of functional biological activities, physical and chemical reactions, such as genome replication, induction of host mRNA cleavage, membrane rearrangement, autophagosome production, NSP polyprotein cleavage, capping, tailing, methylation, RNA double-stranded Uncoiling, etc., and others, play an important role in the virus life cycle. In addition, SARS-CoV-2 contains 4 structural proteins, namely spike (S), nucleocapsid (N), envelope (E) and membrane (M), all of which are encoded by the 3'end of the viral genome. Among the four structural proteins, S protein is a large multifunctional transmembrane protein that plays an important role in the process of virus adsorption, fusion, and injection into host cells, and requires in-depth observation and research.

1S protein is composed of S1 and S2 subunits, and each subunit can be further divided into different functional domains. The S1 subunit has 2 domains: NTD and RBD, and RBD contains conservative RBM. The S2 subunit has 3 structural domains: FP, HR1 and HR2. The S1 subunit is arranged at the top of the S2 subunit to form an immunodominant S protein.

The virus uses the host transmembrane protease Serine 2 (TMPRSS2) and the endosomal cysteine ​​protease CatB/L to enter the cell. TMPRSS2 is responsible for the cleavage of the S protein to expose the FP region of the S2 subunit, which is responsible for initiating endosome-mediated host cell entry into it. It shows that TMPRSS2 is a host factor necessary for virus entry. Therefore, the use of drugs that inhibit this protease can achieve the purpose of treatment.

mRNA-1273

The mRNA encoding the full length of SARS-CoV-2, and the pre-spike protein fusion is encapsulated into lipid nanoparticles to form mRNA-1273 vaccine. It can induce a high level of S protein specific antiviral response. It can also consist of inactivated antigens or subunit antigens. The vaccine was quickly approved by the FDA and has entered phase II clinical trials. The company has announced the antibody data of 8 subjects who received different immunization doses. The 25ug dose group achieved an effect similar to the antibody level during the recovery period. The 100ug dose group exceeded the antibody level during the recovery period. In the 25ug and 100ug dose groups, the vaccine was basically safe and tolerable, while the 250ug dose group had 3 levels of systemic symptoms.

Viral vector vaccines can provide long-term high-level expression of antigen proteins, induce CTLs, and ultimately eliminate viral infections.

1, Ad5-nCov

A vaccine of SARS-CoV-2 recombinant spike protein expressed by recombinant, replication-deficient type 5 adenovirus (Ad5) vector. Load the optimized full-length S protein gene together with the plasminogen activation signal peptide gene into the E1 and E3 deleted Ad5 vectors. The vaccine is constructed by the Admax system derived from Microbix Biosystem. In phase I clinical trials, RBD (S1 subunit receptor binding domain) and S protein neutralizing antibody increased by 4 times 14 days after immunization, reaching a peak on 28 days. CD4+T and CD8+T cells reached a peak 14 days after immunization. The existing Ad5 immune resistance partially limits the response of antibodies and T cells. This study will be further conducted in the 18-60 age group, receiving 1/3 of the study dose, and follow-up for 3-6 months after immunization.

DNA vaccine

The introduction of antigen-encoding DNA and adjuvants as vaccines is the most innovative vaccine method. The transfected cells stably express the transgenic protein, similar to live viruses. The antigen will be endocytosed by immature DC, and finally provide antigen to CD4 + T, CD8 + T cells (by MHC differentiation) To induce humoral and cellular immunity. Some specificities of the virus and the new coronavirus mutant are different from general vaccines and other vaccines. Therefore, it is worth noting the gene expression of the vaccine. Otherwise, the effectiveness and efficiency of the vaccine will be questioned.

Live attenuated vaccine

DelNS1-SARS-CoV2-RBD

Basic influenza vaccine, delete NS1 gene. Express SARS-CoV-2 RBD domain. Cultured in CEF and MDCK (canine kidney cells) cells. It is more immunogenic than wild-type influenza virus and can be administered by nasal spray.

The viral genome is susceptible to mutation, antigen transfer and drift can occur, and spread among the population. Mutations can vary depending on the environmental conditions and population density of the geographic area. After screening and comparing 7,500 samples of infected patients, scientists found 198 mutations, indicating the evolutionary mutation of the virus in the human host. These mutations may form different virus subtypes, which means that even after vaccine immunization, viral infections may occur. A certain amount of increment and strengthening is needed here.

 

Inactivated vaccines, adenovirus vector vaccines, recombinant protein vaccines, nucleic acid vaccines, attenuated influenza virus vector vaccines, etc. According to relevant information, there are dozens of new coronavirus vaccines in the world, and more varieties are being developed and upgraded. Including the United States, Britain, China, Russia, India and other countries, there are more R&D and production units.

AZ vaccine

Modena vaccine

Lianya Vaccine

High-end vaccine

Pfizer vaccine

 

Pfizer-BioNTech

A large study found that the vaccine developed by Pfizer and German biotechnology company BioNTech is 95% effective in preventing COVID-19.

The vaccine is divided into two doses, which are injected every three weeks.

This vaccine uses a molecule called mRNA as its basis. mRNA is a molecular cousin of DNA, which contains instructions to build specific proteins; in this case, the mRNA in the vaccine encodes the coronavirus spike protein, which is attached to the surface of the virus and used to infect human cells. Once the vaccine enters the human body, it will instruct the body's cells to make this protein, and the immune system will learn to recognize and attack it.

Moderna

The vaccine developed by the American biotechnology company Moderna and the National Institute of Allergy and Infectious Diseases (NIAID) is also based on mRNA and is estimated to be 94.5% effective in preventing COVID-19.

Like Pfizer's vaccine, this vaccine is divided into two doses, but injected every four weeks instead of three weeks. Another difference is that the Moderna vaccine can be stored at minus 20 degrees Celsius instead of deep freezing like Pfizer vaccine. At present, the importance of one of the widely used vaccines is self-evident.

Oxford-AstraZeneca

The vaccine developed by the University of Oxford and the pharmaceutical company AstraZeneca is approximately 70% effective in preventing COVID-19-that is, in clinical trials, adjusting the dose seems to improve this effect.

In the population who received two high-dose vaccines (28 days apart), the effectiveness of the vaccine was about 62%; according to early analysis, the effectiveness of the vaccine in those patients who received the half-dose first and then the full-dose Is 90%. However, in clinical trials, participants taking half doses of the drug are wrong, and some scientists question whether these early results are representative.

Sinopharm Group (Beijing Institute of Biological Products, China)

China National Pharmaceutical Group Sinopharm and Beijing Institute of Biological Products have developed a vaccine from inactivated coronavirus (SARS-CoV-2). The inactivated coronavirus is an improved version that cannot be replicated.

 

Estimates of the effectiveness of vaccines against COVID-19 vary.

Gamaleya Institute

The Gamaleya Institute of the Russian Ministry of Health has developed a coronavirus vaccine candidate called Sputnik V. This vaccine contains two common cold viruses, adenoviruses, which have been modified so that they will not replicate in the human body; the modified virus also contains a gene encoding the coronavirus spike protein.

  

New crown drugs

 

There are many small molecule antiviral drug candidates in the clinical research stage around the world. Including traditional drugs in the past and various drugs yet to be developed, antiviral drugs, immune drugs, Gene drugs, compound drugs, etc.

(A) Molnupiravir

Molnupiravir is a prodrug of the nucleoside analog N4-hydroxycytidine (NHC), jointly developed by Merck and Ridgeback Biotherapeutics.

The positive rate of infectious virus isolation and culture in nasopharyngeal swabs was 0% (0/47), while that of patients in the placebo group was 24% (6/25). However, data from the Phase II/III study indicate that the drug has no benefit in preventing death or shortening the length of stay in hospitalized patients.

Therefore, Merck has decided to fully advance the research of 800mg molnupiravir in the treatment of patients with mild to moderate COVID-19.

(B) AT-527

AT-527 is a small molecule inhibitor of viral RNA polymerase, jointly developed by Roche and Atea. Not only can it be used as an oral therapy to treat hospitalized COVID-19 patients, but it also has the potential as a preventive treatment after exposure.

Including 70 high-risk COVID-19 hospitalized patients data, of which 62 patients' data can be used for virological analysis and evaluation. The results of interim virological analysis show that AT-527 can quickly reduce viral load. On day 2, compared with placebo, patients treated with AT-527 had a greater decline in viral load than the baseline level, and the continuous difference in viral load decline was maintained until day 8.

In addition, compared with the control group, the potent antiviral activity of AT-527 was also observed in patients with a baseline median viral load higher than 5.26 log10. When testing by RT-qPCR to assess whether the virus is cleared,

The safety aspect is consistent with previous studies. AT-527 showed good safety and tolerability, and no new safety problems or risks were found. Of course, there is still a considerable distance between experiment and clinical application, and a large amount of experimental data can prove it.

(C) Prokrutamide

Prokalamide is an AR (androgen receptor) antagonist. Activated androgen receptor AR can induce the expression of transmembrane serine protease (TMPRSS2). TMPRSS2 has a shearing effect on the new coronavirus S protein and ACE2, which can promote the binding of viral spike protein (S protein) to ACE, thereby promoting The virus enters the host cell. Therefore, inhibiting the androgen receptor may inhibit the viral infection process, and AR antagonists are expected to become anti-coronavirus drugs.

Positive results were obtained in a randomized, double-blind, placebo-controlled phase III clinical trial. The data shows that Prokalutamide reduces the risk of death in severely ill patients with new coronary disease by 92%, reduces the risk of new ventilator use by 92%, and shortens the length of hospital stay by 9 days. This shows that procrulamide has a certain therapeutic effect for patients with severe new coronary disease, which can significantly reduce the mortality of patients, and at the same time greatly reduce the new mechanical ventilation and shorten the patient's hospital stay.

With the continuous development of COVID-19 on a global scale, in addition to vaccines and prevention and control measures, we need a multi-pronged plan to control this disease. Oral antiviral therapy undoubtedly provides a convenient treatment option.

 

In addition, there are other drugs under development and experimentation. In dealing with the plague virus, in addition to the strict control of protective measures, it is very important that various efficient and safe vaccines and various drugs (including medical instruments, etc.) are the ultimate nemesis and killer of the virus.

 

(A) "Antiviral biological missiles" are mainly drugs for new coronaviruses and mutant viruses, which act on respiratory and lung diseases. The drugs use redundant designs to inhibit new coronaviruses and variant viruses.

(B) "New Coronavirus Epidemic Prevention Tablets" mainly use natural purified elements and chemical structure modifications.

(C) "Composite antiviral oral liquid" antiviral intermediate, natural antiviral plant, plus other preparations

(D) "New Coronavirus Long-acting Oral Tablets" Chemical modification of antiviral drugs, multiple targets, etc.

(E) "New Coronavirus Inhibitors" (injections) are mainly made of chemical drug structure modification and other preparations.

The development of these drugs mainly includes: drug target screening, structure-activity relationship, chemical modification, natural purification, etc., which require a lot of work and experimentation.

Humans need to vigorously develop drugs to deal with various viruses. These drugs are very important for the prevention and treatment of viruses and respiratory infectious diseases, influenza, pneumonia, etc.

The history of human development The history of human evolution, like all living species, will always be accompanied by the survival and development of microorganisms. It is not surprising that viruses and infectious diseases are frequent and prone to occur. The key is to prevent and control them before they happen.

 

This strain was first discovered in India in October 2020 and was initially called a "double mutant" virus by the media. According to the announcement by the Ministry of Health of India at the end of March this year, the "India New Coronavirus Genomics Alliance" composed of 10 laboratories found in samples collected in Maharashtra that this new mutant strain carries E484Q and L452R mutations. , May lead to immune escape and increased infectivity. This mutant strain was named B.1.617 by the WHO and was named with the Greek letter δ (delta) on May 31.

Shahid Jamil, the dean of the Trivedi School of Biological Sciences at Ashoka University in India and a virologist, said in an interview with the Shillong Times of India that this mutant strain called "double mutation" is not accurate enough. B. 1.617 contains a total of 15 mutations, of which 6 occur on the spike protein, of which 3 are more critical: L452R and E484Q mutations occur on the spike protein and the human cell "Angiotensin Converting Enzyme 2 (ACE2)" receptor In the bound region, L452R improves the ability of the virus to invade cells, and E484Q helps to enhance the immune escape of the virus; the third mutation P681R can also make the virus enter the cell more effectively. (Encyclopedia website)

  

There are currently dozens of antiviral COVID-19 therapies under development. The large drugmakers Merck and Pfizer are the closest to the end, as expected, a pair of oral antiviral COVID-19 therapies are undergoing advanced human clinical trials.

Merck's drug candidate is called monupiravir. It was originally developed as an influenza antiviral drug several years ago. However, preclinical studies have shown that it has a good effect on SARS and MERS coronavirus.

Monupiravir is currently undergoing in-depth large-scale Phase 3 human trials. So far, the data is so promising that the US government recently pre-ordered 1.7 million courses of drugs at a cost of $1.2 billion. If everything goes according to plan, the company hopes that the drug will be authorized by the FDA for emergency use and be on the market before the end of 2021.

Pfizer's large COVID-19 antiviral drug candidate is more unique. Currently known as PF-07321332, this drug is the first oral antiviral drug to enter human clinical trials, specifically targeting SARS-CoV-2.

Variant of Concern WHO Label First Detected in World First Detected in Washington State

B.1.1.7 Alpha United Kingdom, September 2020 January 2021

B.1.351 Beta South Africa, December 2020 February 2021

P.1 Gamma Brazil, April 2020 March 2021

B.1.617.2 Delta India, October 2020 April 2021

  

Although this particular molecule was developed in 2020 after the emergence of the new coronavirus, a somewhat related drug called PF-00835231 has been in operation for several years, targeting the original SARS virus. However, the new drug candidate PF-07321332 is designed as a simple pill that can be taken under non-hospital conditions in the initial stages of SARS-CoV-2 infection.

"The protease inhibitor binds to a viral enzyme and prevents the virus from replicating in the cell," Pfizer said when explaining the mechanism of its new antiviral drug. "Protease inhibitors have been effective in the treatment of other viral pathogens, such as HIV and hepatitis C virus, whether used alone or in combination with other antiviral drugs. Currently marketed therapeutic drugs for viral proteases are generally not toxic Therefore, such molecules may provide well-tolerated treatments against COVID-19."

Various studies on other types of antiviral drugs are also gaining momentum. For example, the new coronavirus pneumonia "antiviral biological missile", "new coronavirus prevention tablets", "composite antiviral oral liquid", "new coronavirus long-acting oral tablets", "new coronavirus inhibitors" (injections), etc., are worthy of attention. Like all kinds of vaccines, they will play a major role in preventing and fighting epidemics.

In addition, Japanese pharmaceutical company Shionoyoshi Pharmaceutical is currently conducting a phase 1 trial of a protease inhibitor similar to SARS-CoV-2. This is called S-217622, ​​which is another oral antiviral drug, and hopes to provide people with an easy-to-take pill in the early stages of COVID-19. At present, the research and development of vaccines and various new crown drugs is very active and urgent. Time does not wait. With the passage of time, various new crown drugs will appear on the stage one after another, bringing the gospel to the complete victory of mankind.

  

The COVID-19 pandemic is far from over. The Delta mutant strain has quickly become the most prominent SARS-CoV-2 strain in the world. Although our vaccine is still maintained, it is clear that we need more tools to combat this new type of coronavirus. Delta will certainly not be the last new SARS-CoV-2 variant we encountered. Therefore, it is necessary for all mankind to persevere and fight the epidemic together.

Overcome illness and meet new challenges. The new crown epidemic and various mutated viruses are very important global epidemic prevention and anti-epidemic top priorities, especially for the current period of time. Vaccine injections, research and development of new drugs, strict prevention and control, wear masks, reduce gatherings, strictly control large gatherings, prevent the spread of various viruses Masks, disinfection and sterilization, lockdown of the city, vaccinations, accounting and testing are very important, but this does not mean that humans can completely overcome the virus. In fact, many spreading and new latently transmitted infections are still unsuccessful. There are detections, such as invisible patients, asymptomatic patients, migratory latent patients, new-onset patients, etc. The struggle between humans and the virus is still very difficult and complicated, and long-term efforts and exploration are still needed, especially for medical research on the new coronavirus. The origin of the disease, the course of the disease, the virus invaded The deep-level path and the reasons for the evolution and mutation of the new coronavirus and the particularity of prevention and treatment, etc.). Therefore, human beings should be highly vigilant and must not be taken lightly. The fierce battle between humans and various viruses must not be slackened. Greater efforts are needed to successfully overcome this pandemic, fully restore the normal life of the whole society, restore the normal production and work order, restore the normal operation of society, economy and culture, and give up food due to choking. Or eager for success, will pay a high price.

———————————————————————————————————————————————— ————

 

References References are made to web resources, and related images are from web resources and related websites.

Who official website UN .org www.gavi.org/ispe.org

 

Wikipedia, "The Lancet", "English Journal of Medicine", "Nature", "Science", "Journal of the American Medical Association", etc.

 

Learning from history: do not flatten the curve of antiviral research!

T Bobrowski, CC Melo-Filho, D Korn, VM Alves...-Drug discovery today, 2020-

 

go.drugbank.com/

A critical overview of computational approaches employed for COVID-19 drug discovery

EN Muratov, R Amaro, CH Andrade, N Brown...-Chemical Society..., 2021-pubs.rsc.org

 

Global Research Performance on COVID 19 in Dimensions Database

J Balasubramani, M Anbalagan-2021-researchgate.net

Adoption of a contact tracing app for containing COVID-19: a health belief model approach

M Walrave, C Waeterloos...- JMIR public health and..., 2020-publichealth.jmir.org

 

Prophylactic Treatment Protocol Against the Severity of COVID-19 Using Melatonin

N Charaa, M Chahed, H Ghedira...-Available at SSRN..., 2020-papers.ssrn.com

 

　Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet

  

　Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany, New England Journal of Medicine

The actions of respiratory therapists facing COVID-19

Zhu Jiacheng-Respiratory Therapy, 2021-pesquisa.bvsalud.org

  

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet

 

　Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China, JAMA, February 7

 

Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China, JAMA

 

Delta variant triggers new phase in the pandemic | Science

science.sciencemag.org›

COVID vaccines slash viral spread – but Delta is an unknown

www.nature.com ›articles

Novel coronavirus pneumonia during ophthalmic surgery management strategy and recommendations

YH HUANG, SS LI, X YAO, YR YANG, DH QIN…-jnewmed.com

 

Delta variant: What is happening with transmission, hospital ...

www.bmj.com

Risk of long QT syndrome in novel coronavirus COVID-19

VN Oslopov, JV Oslopova, EV Hazova…-Kazan medical…, 2020-kazanmedjournal.ru

 

Study compares mRNA and adenovirus-based SARS-CoV-2 vaccines ...

www.news-medical.net

First molecular-based detection of SARS-CoV-2 virus in the field-collected houseflies

A Soltani, M Jamalidoust, A Hosseinpour, M Vahedi...-Scientific Reports, 2021-nature.com

 

Covid 19 DELTA Variant Archives-Online essay writing service

sourceessay.com ›tag› covid-19-delta-variant

 

SARS-CoV-2 Delta variant Likely to become dominant in the ...

www.news-medical.net

 

Compilation postscript

Once Fang Ruida's research literature on the new crown virus and mutant virus was published, it has been enthusiastically praised by readers and netizens in dozens of countries around the world, and has proposed some amendments and suggestions. Hope to publish a multilingual version of the book as an emergency To meet the needs of many readers around the world, in the face of the new crown epidemic and the prevention and treatment of various mutant viruses, including the general public, college and middle school students, medical workers, medical colleagues and so on. According to the English original manuscript, it will be re-compiled and published. Inconsistencies will be revised separately. Thank you very much.

 

Jacques Lucy, Geneva, Switzerland, August 2021

 

*********************************************************************

 

Leader mondial, scientifique, scientifique médical, virologue, pharmacien et professeur Fangruida (F.D Smith) sur l'épidémie mondiale et l'ennemi juré et la prévention des nouveaux coronavirus et virus mutants (Jacques Lucy 2021v1.5)

_-----------------------------------------

L'ennemi juré et le tueur du nouveau coronavirus et des virus mutés - Développement conjoint de vaccins et de médicaments (Fangruida) Juillet 2021

* La particularité des nouveaux coronavirus et des virus mutants * Le large spectre, la haute efficacité, la redondance et la sécurité de la conception et du développement du nouveau vaccin contre le coronavirus, Redondance et sécurité

* Nouvelle modification de la structure chimique des médicaments contre les coronavirus * Conception et dépistage des médicaments assistés par ordinateur. *"Missile biologique antiviral", "Nouveaux comprimés anti-épidémiques contre le coronavirus", "Liquide oral antiviral composite", "Nouveaux comprimés oraux à action prolongée contre le coronavirus", "Nouveaux inhibiteurs de coronavirus" (injection)

——————————————————————————

(leader mondial, scientifique, scientifique médical, biologiste, virologue, pharmacien, FD Smith) "The Nemesis and Killer of New Coronavirus and Mutated Viruses-The Joint Development of Vaccines and Drugs" est un important document de recherche scientifique. Il a maintenant été révisé et réédité par l'auteur original à plusieurs reprises. La compilation est publiée et publiée selon le manuscrit original pour répondre aux besoins des lecteurs et des internautes du monde entier. En même temps, elle est également très bénéfique pour le grand nombre de chercheurs en médicaments cliniques médicaux et de divers experts et universitaires. Nous espérons qu'il sera corrigé dans la réimpression.------Compilé par Jacques Lucy à Genève, août 2021

  

-------------------------------------------------- ---------------------

    

Selon les statistiques en temps réel de Worldometer, vers 6h30 le 23 juillet, il y avait un total de 193 323 815 cas confirmés de nouvelle pneumonie coronarienne dans le monde, et un total de 4 150 213 décès. Il y a eu 570 902 nouveaux cas confirmés et 8 766 nouveaux décès dans le monde en une seule journée. Les données montrent que les États-Unis, le Brésil, le Royaume-Uni, l'Inde et l'Indonésie sont les cinq pays avec le plus grand nombre de nouveaux cas confirmés, et l'Indonésie, le Brésil, la Russie, l'Afrique du Sud et l'Inde sont les cinq pays avec le plus grand nombre de nouveaux décès.

 

Les nouvelles souches de coronavirus et de mutants delta ont été particulièrement graves ces derniers temps. De nombreux pays et lieux ont repris vie et le nombre de cas n'a pas diminué, mais a augmenté.

, Il est digne de vigilance. Bien que de nombreux pays aient renforcé la prévention et le contrôle des vaccins et d'autres mesures de prévention et de contrôle, il existe encore de nombreuses lacunes et carences dans la suppression et la prévention du virus. Le nouveau coronavirus et diverses souches mutantes présentent un certain degré d'antagonisme par rapport aux médicaments traditionnels et à la plupart des vaccins. Bien que la plupart des vaccins aient de grandes propriétés anti-épidémiques et aient des effets et une protection importants et irremplaçables pour la prévention et le traitement, il est impossible d'empêcher complètement la propagation et l'infection des virus. La propagation de la nouvelle pneumonie à virus couronne a été retardée de près de deux ans. Il y a des centaines de millions de personnes infectées dans le monde, des millions de décès, et le temps est long, la propagation est généralisée et des milliards de personnes dans le monde sont parmi Les dommages causés par le virus sont assez terribles, c'est bien connu. Plus urgent

Ce qui est plus grave, c'est que le virus et les souches mutantes n'ont pas complètement reculé, surtout que de nombreuses personnes sont encore infectées et infectées après avoir été injectées avec divers vaccins.L'efficacité du vaccin et la résistance du virus mutant sont dignes des scientifiques médicaux, virologues , les pharmacologues Les zoologistes et autres réfléchissent et analysent sérieusement. La situation épidémique actuelle dans les pays européens et américains, la Chine, le Brésil, l'Inde, les États-Unis, la Russie et d'autres pays s'est considérablement améliorée par rapport à l'année dernière.Cependant, les chiffres pertinents montrent que la situation épidémique mondiale ne s'est pas complètement améliorée, et certains pays et régions sont encore très graves. En particulier, après une utilisation intensive de divers vaccins, des cas surviennent encore, et dans certains endroits ils sont encore très graves, ce qui mérite une grande vigilance. Les mesures de prévention et de contrôle sont très importantes.De plus, les vaccins et divers médicaments antiépidémiques sont les premiers choix nécessaires, et les autres méthodes sont irremplaçables. Il est particulièrement important de développer et de développer des médicaments complets, des médicaments antiviraux, des médicaments immunitaires et des médicaments génétiques. Les expériences de recherche sur les nouveaux coronavirus et virus mutants nécessitent une analyse plus rigoureuse et approfondie des données, des tissus pathogènes pathologiques, des gènes cellulaires, de la chimie moléculaire, de la chimie quantique, etc., ainsi que de la chimie moléculaire des vaccins, de la physique quantique, de la biologie quantique, de l'histologie cytologique, la chimie médicinale et les médicaments Et les symptômes, l'efficacité, la sécurité, l'efficacité à long terme, etc. du vaccin, bien sûr, y compris des dizaines de milliers de cas cliniques et de décès et d'autres informations et preuves de première main. La tâche de l'ARN (acide ribonucléique) dans le corps humain est d'utiliser les informations de notre matériel génétique ADN pour produire des protéines. Il accomplit cette tâche dans le ribosome, la zone productrice de protéines de la cellule. Le ribosome est le lieu où se produit la biosynthèse des protéines.

La médecine en profite : dans la vaccination, l'ARNm produit artificiellement fournit aux ribosomes des instructions pour construire des antigènes pathogènes contre lesquels lutter, par exemple, la protéine de pointe du coronavirus.

Les vaccins vivants traditionnels ou les vaccins inactivés contiennent des antigènes qui provoquent la réaction du système immunitaire. Le vaccin à ARNm est produit dans la cellule

(1) La spécificité des nouveaux coronavirus et virus mutants, etc., virologie et chimie quantique des virus mutants, physique quantique, microbiologie quantique

(2) Nouvelle conception de vaccin couronne, biologie moléculaire et structure chimique, etc.

(3) La généralité et la particularité du développement de nouveaux médicaments contre le coronavirus

(4) Diverses conceptions de médicaments pour la pneumonie à nouveau coronavirus, la chimie médicinale, la pharmacologie, etc., les cellules, les protéines, l'ADN, la chimie des enzymes, la chimie quantique pharmaceutique, la physique quantique pharmaceutique, la biochimie humaine, la biophysique humaine, etc.

(5) Les caractéristiques d'évolution et de mutation du nouveau coronavirus et de divers virus mutants, la nature à long terme, la répétabilité, la résistance aux médicaments et la résistance épidémique du virus, etc.

(6) Pneumonie à nouveau coronavirus et transmission infectieuse de divers nouveaux coronavirus et leurs particularités

(7) La transmission invisible de la pneumonie à nouveau coronavirus et de divers virus mutants chez l'homme ou l'animal, et la symbiose mutuelle de l'infection croisée de diverses bactéries et virus sont également l'une des causes très graves de dommages graves aux nouveaux coronavirus et virus mutants. La virologie, la pathologie, l'étiologie, le séquençage des gènes, la cartographie des gènes et un grand nombre d'études analytiques ont montré qu'il existe de nombreux cas en Chine, aux États-Unis, en Inde, en Russie, au Brésil et dans d'autres pays.

(8) Pour la prévention et le traitement symptomatiques du nouveau coronavirus, la combinaison de divers vaccins et de di

fashion.doubleasl.com/blog/what-is-in-town/

CAPE CANAVERAL, Fla. – Inside the Vehicle Assembly Building at NASA's Kennedy Space Center in Florida, construction workers continue with refurbishment and upgrades to the 175-ton crane on the ground floor of the transfer aisle. The crane's 45-year-old controls are being upgraded to improve reliability, precision and safety. The Ground Systems Development and Operations Program is overseeing upgrades and modifications to the crane so that it can support lifting needs for NASA and other exploration vehicles, including the agency's Space Launch System and Orion spacecraft. Photo credit: NASA/Kim Shiflett

la modification consiste à offrir a cette dame des jambes beaucoup plus articulées que d'origine.aucune figurines n'a souffert durant l'opération ( c'est ce qu'il m'a semblais! )

 

the change is to offer this lady has much more articulated legs that original. no figures have suffered during the operation (that is what it seemed to me!)

Go to Page 35 in the Internet Archive

Title: Modifications àdifférents procédés opératoires : amputation de la jambe, désarticulation des quatre derniers métacarpiens, désarticulation de l'ÃÂépaule, phimosis, extirpation de testicule

Creator: Montes de Oca, Francisco, -1884

Publisher: Paris : G. Masson

Sponsor: Wellcome Library

Contributor: Wellcome Library

Date: 1891

Language: fre

Description: 31 pages, 3 unnumbered leaves of plates : 24 cm

First published in 1874, edited by Daniel M. Velez

 

If you have questions concerning reproductions, please contact the Contributing Library.

 

Note: The colors, contrast and appearance of these illustrations are unlikely to be true to life. They are derived from scanned images that have been enhanced for machine interpretation and have been altered from their originals.

 

Read/Download from the Internet Archive

 

See all images from this book

See all MHL images published in the same year

See all images from Wellcome Library

+++ DISCLAIMER +++

Nothing you see here is real, even though the conversion or the presented background story might be based historical facts. BEWARE!

 

Some background:

NAe São Paulo is a Clemenceau-class aircraft carrier currently in service with the Brazilian Navy. São Paulo was first commissioned in 1963 by the French Navy as Foch and was transferred in 2000 to Brazil, where she became the new flagship of the Brazilian Navy. In December 2014 it was announced that São Paulo will be expected to continue active service until 2039, at which time the vessel will be nearly 80 years old.

 

From this carrier, the Marinha do Brasil operates its only fixed-wing aircraft, and these were initially A-4 Skyhawks. In 1997 Brazil negotiated a $70 million contract for purchase of 20 A-4KU and three TA-4KU Skyhawks from Kuwait. The Kuwaiti Skyhawks, modified A-4Ms and TA-4Js delivered in 1977, were among the last of those models built by Douglas. The Kuwaiti Skyhawks were selected by Brazil because of low flight time, excellent physical condition, and a favorable price tag. The Brazilian Navy Re-designated AF-1 and AF-1A Falcões (Hawks), the ex-Kuwaiti Skyhawks arrived in Arraial do Cabo on 5 September 1998.

 

Anyway, the Skyhawks' life span was limited and in 2005 the Brazilian Navy started looking for a potential replacement, while the AF-1s were to kept operational due to limited military budgets. On 14 April 2009, Brazlian aircraft manufacturer EMBRAER signed a contract to modernize 12 Skyhawks, nine AF-1s (single-seat) and three AF-1As (two-seat). This upgrade will restore the operating capacity of the Navy 1st Intercept and Attack Plane Squadron (VF-1). The program includes restoring the aircraft and their current systems, as well as implementing new avionics, radar, power production, and autonomous oxygen generating systems. The first of the 12 modified Skyhawks was delivered on 27 May 2015. EMBRAER stated that the modifications would allow the aircraft to remain operational until 2025, by which time a successor was to be fully operational.

 

Several replacement candidates were evaluated under Brazil's F-X2 fighter program together with the Air Force which was looking to replace its Northrop F‐5EM and Dassault Mirage 2000C aircraft. In October 2008, Brazil selected three finalists: the Dassault Rafale, the Boeing F/A-18 Super Hornet, and the SAAB JAS 39 Gripen. The Brazilian Air Force initially planned to procure at least 36 and possibly up to 120 aircraft later, while the Brazilian Navy was looking for 24 aircraft (20 single seater and 4 two-seaters with dual controls) until 2025.

 

In February 2009, SAAB submitted a tender, and on 5 January 2010, reports claimed that the final evaluation report placed the Gripen ahead of other contenders; the decisive factor was reportedly lower unit and operational costs, the most compact size and the Swedish manufacturer's willingness to accept EMBRAER as a technological partner for the aircraft's further development, especially for the navalized version.

 

Amid delays due to financial constraints, President Dilma Rousseff announced in December 2011 the Gripen NG's selection and the start of a joint Swedish-Brazilian joint venture called SABRA. Argentina and Ecuador were interested in procuring Gripens from or through Brazil, and Mexico and Argenitina were potential export targets for SABRA's navalized Gripen derivative that was tailored to the Marinha do Brasil's needs.

 

The respective SABRA aircraft was appropriately christened "Grifo" and the development of thei 4th generation fighter started immediately after closing the cooperation deal in 2011. While based on the SAAB 39, the Grifo became a very different aircraft, due to several factors. The major influence was the carrier operation capability, which called for major structural modifications and enforcements as well as special equipment like foldable wings, a strengthened landing gear, an arrester hook and a new engine that would better cope with the naval environment than the Swedish RM 12 engine, a derivative of the General Electric F404-400.

 

Additionally, the mission focus of air superiority with additional attack capabilities was reversed, and the need for excellent low speed handling for carrier approaches was requested.

 

This led to a complelety different aircraft layout, with the SAAB 39's instable canard design being changed into a conservative aircraft with conventional tailplanes. The nose section was shortened in order to provide the pilot with a better field of view, while the more powerful F414-EPE afterburning turbofan was moved slightly forward due to CG reasons, resulting in a slightly shortened rear fuselage.

 

A mock-up of the new aircraft for the Brazlian Navy was presented and approved in early 2012, and the government placed an official order for two prototypes. Even though the Grifo appeared like a completely different aircraft, it shared a lot of elements with the SAAB 39, so that development time and costs could be reduced to a minimum - and the first prototype, internally designated EMB 391-001, made its maiden flight in early 2013. The second aircraft followed 3 months later.

 

The Grifo's equipment includes an AN/APG-79 active electronically scanned array (AESA), capable of executing simultaneous air-to-air and air-to-ground attacks, and providing higher quality high-resolution ground mapping at long standoff ranges. The AESA radar can also detect smaller targets, such as inbound missiles, and can track air targets beyond the range of the aircraft's air-to-air missiles, which include the AIM-9 Sidewinder for close range and the AIM-120 AMRAAM for medium range.

 

The Grifo features, like the Gripen fighter, an advanced and integrated electronic warfare suite, capable of operating in an undetectable passive mode or to actively jam hostile radar; a missile approach warning system passively detects and tracks incoming missiles.

 

The Grifo can be tailored to specific missions through external sensor pods, e .g. for reconnaissance and target designation. These include Rafael's LITENING targeting pod, Saab's Modular Reconnaissance Pod System or Thales' Digital Joint Reconnaissance Pod. On the Brazilian Navy's request the Grifo is also designed that it can be equipped with an aerial refueling system (ARS) or "buddy store" for the refueling of other aircraft, filling the tactical airborne tanker role.

 

The two prototypes completed a thorough test program until summer 2015 and subsequently went on a sales tour in South America and Asia. In the meantime, serial production started at EMBRAER's Gavião Peixoto in November 2015. The first serial machines, now officially designated AF-2A, arrived at the Brazilian Navy's São Pedro da Aldeia air base where a new Intercept and Attack Plane Squadron, VF-2 'Arquieros' (Archers) was founded. The squadron became operational in April 2016 and Grifos embarked on NAe São Paulo for the first time in September 2016, serving alongside the venerable AF-1.

  

General characteristics:

Crew: 1

Payload: 5,300 kg (11,700 lb)

Length: 13,54 m (44 ft 4 in)

Wingspan (incl. wing tip launch rails): 8.32 m (27 ft 2 in)

Height: 4.25 m (13 ft 11 in)

Wing area: 30.0 m² (323 ft²)

Empty weight: 6,800 kg[330] (14,990 lb)

Loaded weight: 8,500 kg (18,700 lb)

Max. takeoff weight: 14,000 kg (31,000 lb)

Wheel track: 2.4 m (7 ft 10 in)

Powerplant:

1 × General Electric F414-EPE afterburning turbofan with

a dry thrust of 54 kN (12,100 lbf) and 85 kN (19,100 lbf) with afterburner

 

Performance:

Maximum speed: Mach 2 (2,204 km/h (1,190 kn; 1,370 mph) at high altitude

Combat radius: 800 km (497 mi, 432 nmi)

Ferry range: 3,200 km (1,983 mi) with drop tanks

Service ceiling: 15,240 m (50,000 ft)

Wing loading: 283 kg/m² (58 lb/ft²)

Thrust/weight: 0.97

Maximum g-load: +9 g

 

Armament:

1× 27 mm Mauser BK-27 Revolver cannon with 120 rounds

Eight hardpoints (three on each wing and two under fuselage)

for a wide range of guide and unguided ordnance of up to 14,330 lb (6.5 t)

  

The kit and its assembly:

The fictional Grifo is the result of a generic idea of converting a canard layout aircraft like the Saab Viggen into a conventional design. The Viggen was actually a serious candidate, but then I found an Italeri Gripen in the stash without a real purpose (it had been cheap, though), and with Brazil's real world procurement as background, the more conservative Grifo was born.

 

I wanted to use as many OOB Gripen parts as possible, and there are actually only a few external donations involved – with the outlook of converting further Gripens this way. You never know… ;)

 

Work started with the wings, which were cut off of the fuselage shell. Having the landing gear retract into the fuselage (much like the X-29) is a convenient detail of the Gripen, making the wing transplantation easier than on a Viggen where the wells have to be moved, too.

 

The original canard attachment points were faired over/hidden. The pointed Gripen nose with its pitot was cut off and replaced by a shorter, more stocky nose tip - from an F-4 Phantom II IIRC. Once the fuselage was completed, the wings were mounted, closer to the air intakes. This went smoothly, only some gaps on the undersides had to be filled.

 

Once the wings were in place I had to make a decision concerning the stabilizers. Despite the plan to use as many OOB parts as possible I found the OOB canards to be too sharply swept and considered several donation options.

I eventually settled for the most unique option: the stabilizers are actually main wings from a (rather malformed) Italeri/Dragon 1:200 F-117 that comes as a set with the B-2 bomber. A part of the F-117’s fuselage flank was cut off and taken over to the Grifo, too, so that these create ‘muscular’ bulges.

 

The stabilizers were mounted on scratched consoles/trailing wing root extensions that were somewhat inspired by the F-16’s tail design – putting the stabilizers directly onto the fuselage would have looked awkward, and with this solution I was able to extend the Gripen’s BWB-design all along the fuselage. As a side effect these consoles also offered a plausible place for rearward chaff dispensers.

 

The rear fuselage was shortened by 3mm, too – through the shorter nose and the wings further forward, the rest of the aircraft looked rather tail-heavy. While 3mm does not sound much, it helped with overall proportions.

 

The cannon fairing and the OOB pylons were taken over, as well as the cockpit interior. For carrier operations, several details were added, though: folding wing mechanism seams were engraved on the wings and an arrester hook with a fairing added under the tail section, flanked by new stabilizer fins.

 

The landing gear was basically taken OOB, too, but lengthened with styrene inserts for a higher stance: the main struts are now 2mm longer, while the front strut is 3mm taller. The latter was reversed, so that a catapult hook could be added to the front side, and slightly bigger wheels were mounted, too, so that the Grifo now has a rather stalky stance with a nose-up attitude. Simple, but effective!

 

The Sidewinders were taken OOB while the pair of AGM-84 Harpoon comes from Italeri’s 1:72 NATO weapons set.

 

Painting and markings:

I used the contemporary AF-1 paint scheme in three shades of grey as benchmark. These are FS 36187 (RAF Ocean Grey), FS 36307 (Flint Grey) and FS 36515 (Canadian Voodoo Grey) - sourced from a painting guide from Brazilian decal manufacturer FCM and backed by other knowledgeable sources from the region, too. And while the Ocean Grey appears a bit dark, I think that overall the colors are authentic. All paints are Modelmaster enamels.

 

After basic painting a light black ink wash was applied and panels highlighted through dry-brushing with lighter tones.

 

The cockpit interior was painted in Neutral Grey (FS 36173), while the landing gear became all-white.

The Brazilian Navy markings had to be improvised - there are 1:72 AF-1 decals available, but either not obtainable or prohibitively expensive - or both. Therefore I rather improvised, with basic Brazilian Navy markings from a vintage FCM Decal sheet for various Brazilian aircraft.

 

The respective roundels and codes actually belong to helicopters, and I had to wing it somehow. Unfortunately, the old FCM decals turned out to be ...old. Brittle and very delicate, application was already messy and they did not adhere well to the model. To make matters worse the acrylic varnish turned cloudy, so that a lot of paintwork repair had to be done - not helping much with a satisfactory kit finish. :(

  

Another interesting conversion – I am amazed how purposeful the Grifo looks. It reminds me with its high stance of a modern A-4 Skyhawk (what it somehow is), and there’s also some Super Étendard in it, esp. in the profile? At some point before painting it also had a somewhat Chinese look - maybe because the top view and the wing planform reminds of the classic MiG-21…? The wings might have been placed 3-4mm further backwards, since it is always difficult to judge proportions while work is still, but the Grifo looks convincingly like a real aircraft (model).

 

Aeronaves bonita! :D

Generated by me, Tool used AI Stable Diffusion

Image made with dalle3 + manual modifications with photoshop.

Front LED strobes & N/S locker. Both N/S & O/S lockers go right up to the bulkhead. Just need to decide wether to take out the back fuel tank next and put some thing in its place prehaps a spare wheel tray or underbox, mmmmm!!!

as requested ^^

Modified Brick Arms AK47.

Project designed by Ashley Kannan

Saint- Nicolas Blasimon was once a small monastery under the patronage of Saint -Maurice. It depended successively La Sauve and Saint Jean d'Angely . Mentioned in the tenth century , it has left little trace in history. Its unique four- vaulted bays ship warheads is the result of numerous modifications that have affected the built in small rubble early church.

the facade

The happiest part of these works is the rehabilitation of the facade, the mid-twelfth century. We then drew up a rectangular screen divided by four pairs of slender engaged columns, which still exists at the end of an avenue of trees in a romantic desire valley. Few works tremble such a joy. At ground level, the profile of column bases - two tori surrounding a studded bra besants - continues uninterrupted in stylobate tompu at the foot of the frontispiece to provide a sitting elegantly engineered, stable and pleasant to the eye. At the center of the ground floor opens a broken door with five arches carved ébrasent is largely under a beautiful archi . To meet this monumental entrance, right and left, in the frame drums paired, two small arches , drawing feints doors whose single roller falls on two columns facing each other. Almost halfway up a thick cornice corbels , covered with a little glaze, powerfully underlines the nakedness of the floor, where a large bay semicircular slit in the thirteenth century geminal arcade, stands alone in center of the facade . Both narrow and slender side panels to the floor overcome the blind arches on the ground floor remained undecorated , indulging in their eye recount the beauty of the limestone unit blond . If a second ledge was provided at very simple capitals crowning the tall columns of the facade, it has not been built , and there is , fortunately, not weighed down by the perfection of this sensitive geometry erected to serve as a backdrop to one of the most prodigious creations carved Aquitaine. The fifteenth century only built over the entire width of the frontispiece, a bell gable wall at the bottom decorated with hooks, weighted at birth crawling by two small pinnacles ; four bays aligned pointed arch surmounted by a fifth the same ajourent and make the set as a slight additional arcade open sky background.

sculpture

Concentrated in the blind bays , the central portal , window and coving, carved ornament of the church has largely escaped the revolutionary vandalism, which however mutilated heads in 1793 , and projects restaurateurs Giraud in 1848. A foodservice retailer also conducted with great care in recent years, not only partially affected. This is one of the vertices of the Romanesque Southwest in its final phase : the splendor of the figures, verve and freedom of invention ornament, grace and elegance that give the whole sensitivity and the address of a stunning scissors are strictly exceptional . As the lateral portal, fat stems, swollen arcades, run and hug wholesale foliage almost completely detached from the mass of the abacus, and even erosion of limestone lends them, if possible, a charm more. It is the same for palmettes second, third and fifth arches from inside. Their unusual size, strength and perfection of their curves, the nervousness of the chasing and their full implementation contribute to making the exceptional setting entrench storied arches . The capitals are in the same vein, but wear makes them sometimes tricky to decipher. Bases of the northern arcade, are , left, two birds strangled by a man they peck ears, right, two very spoiled monsters. The southern false door shows a vegetable basket and characters amidst foliage. The central portal, the line offers baskets , left to right: a lion face, a marked Far Eastern character entwined basil tamed by man, griffins, a juggler dancing accompanied by two musicians playing the sitting a lyre , the other viola - a scene that particularly well astragalus loaded beads and saw- tooth stresses - and a worn down characters about which has just been restored. The splay of this right under the arch intrados a basket of modern scrolls, then a man between two lions, a man supported by two birds, two characters pruning a tree and a tasty vegetable trash the lower half of which is new.

 

But the most beautiful part of this program lies in its arches with figures. The concave roller, first, where four angels standing on the clouds lifted their high - haloed wings instead of missing their heads, accompanied by slight rise in the arch of the Paschal Lamb who sat in the key, and is no longer present by its circular mandorla. They hold the instruments of the Passion, including the crown of thorns is still discernible on the left, and maybe whip whipping. They are the brothers of the great creations that name: Aulnay, Pont l'Abbé, Chadenac . As are relatives of the same current figures of Virtues Vices slaying in one of the many illustrations of Psychomachia, probably the most beautiful. It is effortless that the thin ideal figures of the Virtues, whose clothes small tight folds mold body that extends to the extreme, outweigh the Vices, hideous beasts swarming and crawling they trample . Sword or spear, protected by those they wore long shields to 1160-1170, and that suits their elegant mannerisms, they dominate more than they fight victorious, if one may say, from eternity. Languedoc distant origin of this growth is still perceptible in plastic Virtue right at the bottom of the arch, the most beautiful perhaps, crossing her long legs like a courtship dance.

The archivolte is dedicated to the hunt. Departures of the arc admirable isolated plant stylize comm: in staging Shakespeare, the dark world of the forest. The tree on the left has a tiny archer. Unfolds over a pack, encouraged by a ringer wrong; Dog sitting waiting for the signal to the end hallali where deer, forced is taken hock and throat, and still covered by a second archer, found that simultaneous presentation of successive elements of an action so dear to the narrative technique of the novel world. The right half of the arch has suffered more. One can see the struggle of a centaur against a monster, and a beautiful character drawn, leaning on his spear. Such is the extraordinary portal, crowned with the glory that should by a cornice with beautiful corbels responsible for animal and human figures wearing masks cord carved entablature, worthy of its tasty fullness and surmounted buxom palmettes of the single bay in the center of the facade.

 

(from: Romanesque Guyenne ; Pierre Dubourg Noves , Ed Zodiac , Coll Night Time, 1979)

CAPE CANAVERAL, Fla. – Modifications continue on the Mobile Launcher, or ML, at the Mobile Launcher Park Site at NASA’s Kennedy Space Center in Florida. Scaffolding, or work platforms, have been installed around the base of the tower on the ML to continue upgrades and modifications to the structure. The ML is being modified and strengthened to accommodate the weight, size and thrust at launch of NASA's Space Launch System, or SLS, and Orion spacecraft. The ML is one of the key elements of ground support equipment that is being upgraded by the Ground Systems Development and Operations Program at Kennedy. The ML will carry the SLS rocket and Orion spacecraft to Launch Pad 39B for its first uncrewed mission, Exploration Mission-1, in 2018. Photo credit: NASA/Kim Shiflett

Posted via web from izatrini's posterous

A nearside view of MB90 taken at the same time as my previous upload showing how the centre door had been removed by Location Facilities.

The doors and associated equipment were reinstated not long after the bus was initally bought for preservation in 1990 using parts from a scrap MBS also operated by this company if I remember correctly.

All contents presented here are copyrighted © by Mehedi Akash, Unauthorized use, modification and republications are prohibited and strictly discouraged. Contact @01674836867 for any further details. Thank you

  

Facebook Page - www.facebook.com/Akashd600

thumbnail for album

Easy stuff to do to tighten up your iOtpron SmartEQ or Pro and make it enjoyable to use.

Working on fitting this into a layout I have and the original Castle was too wide for the space so I followed the basic instructions and just about kept everything (had to add in some darker mason bricks to stretch it) to fit in a 4 x 20 space.

 

Wanted a little interior details with inner courtyard, parapets, trees near a watering hole for the citizens inside the castle.

modification

+++ DISCLAIMER +++

Nothing you see here is real, even though the conversion or the presented background story might be based on historical facts. BEWARE!

  

Some background:

The Parder was a successor of the Tiger I & II tanks, combining the latter's thick armor with the armor sloping used on the Panther medium tank (which was, in fact, inspired by Soviet designs, most of all by the T-34). While several Entwicklungspanzer designs were under development, the Parder was a short-term attempt to overcome the Tiger II's main shortcoming: its weight of almost seventy metric tons (it was protected by up to 180 mm/7.1" of front armor!), the resulting lack of mobility and an overburdened drivetrain originally intended for a lighter vehicle. Leaking seals and gaskets also took their toll on reliability.

 

In order to keep the development phase short the Parder used basically the same chassis as the Tiger II, as well as the engine, transmission and the long barreled 8.8 cm KwK 43 L/71 gun. But it reveiced a new hull with optimized armor and many detail modifications that reduced the overall weight by more than ten tons, getting overall weight back to the level of the Tiger I

 

The SdKfz. 190 used a conventional hull design with sloped armor from all sides, resembling the layout of the T-34 a lot. Its was so effective that the front armor could be reduced to 120 mm (4.7 in) with only little loss in protection. The crew was reduced to four, only the driver remained in the hull and the front machine gun was omitted, too.

 

The 'Parder' (archaic German term for leopard), how the vehicle was semi-officially christened by the Entwicklungskommission Panzer, had a rear mounted engine and used nine steel-tired overlapping road wheels per side with internal springing, mounted on transverse torsion bars.

 

The turret had been designed by Krupp and featured a rounded front and steeply sloped sides, with a difficult-to-manufacture curved bulge on the turret's left side to accommodate the commander's cupola (often related to as the "Porsche" turret). The powerful 8.8 cm KwK 43 L/71 gun was combined with the Turmzielfernrohr 9d (German "turret telescopic sight") monocular sight by Leitz - a very accurate and deadly weapon.

 

During practice, the estimated probability of a first round hit on a 2 m (6 ft 7 in) high, 2.5 m (8 ft 2 in) wide target only dropped below 100 percent at ranges beyond 1,000 m (0.62 mi), to 95–97 percent at 1,500 metres (0.93 mi) and 85–87 percent at 2,000 m (1.2 mi), depending on ammunition type. Recorded combat performance was lower, but still over 80 percent at 1,000 m, in the 60s at 1,500 m and the 40s at 2,000 m.

 

Penetration of armored plate inclined at 30 degrees was 202 and 132 mm (8.0 and 5.2 in) at 100 m (110 yd) and 2,000 m (1.2 mi) respectively for the Panzergranate 39/43 projectile (PzGr—armor-piercing shell), and 238 and 153 mm (9.4 and 6.0 in) for the PzGr. 40/43 projectile between the same ranges. The Sprenggranate 43 (SpGr) high-explosive round was available for soft targets, or the Hohlgranate or Hohlgeschoss 39 (HlGr—HEAT or High explosive anti-tank warhead) round, which had 90 mm (3.5 in) penetration at any range, could be used as a dual-purpose munition against soft or armored targets.

 

Like all German tanks, the Parder had a gasoline engine; in this case the same 700 PS (690 hp, 515 kW) V-12 Maybach HL 230 P30 which powered the Panther, Tiger I and Tiger II tanks. The Tiger II was under-powered with it, though, and consumed a lot of fuel, which was in short supply for the Germans, but in the Parder it proved to be adequate, even though performance was not oustanding. The transmission was the Maybach OLVAR EG 40 12 16 Model B, giving eight forward gears and four reverse, which drove the steering gear.

 

In order to distribute the tank's weight an extra wide track was used, but this meant that each tank was issued with two sets of tracks: a normal "battle track" and a narrower "transport" version used during rail movement. The transport tracks reduced the overall width of the load and could be used to drive the tank short distances on firm ground.

 

The Parder was, like many German late war designs, rushed into combat, but thanks to its Tiger I & II heritage many mechanical teething problems had already been corrected. Reliability was considerably improved compared to the much heavier Tiger II, and the Parder did prove to be a very effective fighting vehicle, especially in a defensive role. However, some design flaws, such as its weak final drive units, were never corrected due to raw material shortages, and more tanks were given up by the crews than actually destroyed in combat.

 

The Parder was issued to heavy tank battalions of the Army (Schwere Heerespanzerabteilung – abbreviated s.H.Pz.Abt) where it replaced the Tiger I & II.

  

Specifications:

Crew Four (commander, gunner, loader, driver)

Weight 54 tonnes (60 short tons)

Length 7.02 metres (23 ft in) (hull only)

10.64 metres (34 ft 10 1/3 in) with gun forward

Width 3.88 metres (12 ft 9 in)

4.14 metres (13 ft 6 3/4 in) with optional Thoma shields

Height 2.84 metres (9 ft 4 in) w/o AA machine gun

Suspension torsion-bar

Ground clearance: 495 to 510 mm (1 ft 7.5 in to 1 ft 8.1 in)

Fuel capacity: 820 l (180 imp gal; 220 US gal)

 

Armor:

30–120 mm (1.2 – 4.7 in)

 

Performance:

Speed

- Maximum, road: 41.5 km/h (25.8 mph)

- Sustained, road: 38 km/h (24 mph)

- Cross country: 15 to 20 km/h (9.3 to 12.4 mph)

Operational range: 240 km (150 mi)

Power/weight: 12,96 PS/tonne (11,5 hp/ton)

 

Engine:

V-12 Maybach HL 230 P30 gasoline with 700 PS (690 hp, 515 kW)

 

Transmission:

Maybach OLVAR EG 40 12 16 B (8 forward and 4 reverse)

 

Armament:

1× 8.8 cm KwK 43 L/71 with 80 rounds

1× co-axial 7.92 mm Maschinengewehr 34 with 3.000 rounds

  

The kit and its assembly:

Something different… a whif tank! This was spawned from curiosity and the “wish” to build a German vehicle that would fit right into the E-25… E-100 range of experimental tanks.

It was to become a battle tank, and while browsing options and donation kits, I settled upon a replacement for the formidable but heavy and cumbersome Tiger B, also known as Tiger II, Königstiger or (wrongfully translated) King Tiger.

 

Anyway, creating a tank that would look (late war) German and still be whiffy was trickier than expected, and finally easier than expected, too. My solution would be a kit bashing: using many Tiger B parts (including the stylish Porsche tower and the running gear) and combining it with a hull that would offer better armor angles and look less “boxy”.

 

I effectively bashed two kits: one is the excellent 1:72 early Tiger B from Dragon, the other is Roden’s Soviet IS-3 tank – also very nice, even though the styrene is somewhat brittle.

 

My biggest fear was the running gear – combining the IS-3 hull with the Tiger B’s totally different legs scared me a lot – until I found that the parts from both kits (the Tiger B’s lower hull with all the suspension and the IS-3’s upper hull) could be combined rather easily combined. Just some cuts and improvised intersections, and the “new” tank hull was done!

 

As a side effect, the huge turret moved forward, and this considerably changes the silhouette. The IS-3’s opening had only to be widened slightly in order to accept the Porsche turret. Things matched up pretty well, also concerning size and proportions.

 

Otherwise, not much was changed. All wheels and tracks come from the Trumpeter Tiger B, the turret was also borrowed wholesale. I just changed some details (e. g. moving the spare track elements to the hull front), added some handles and also a heavy AA machine gun on the commander’s cupola, which is OOB, too.

 

Too simple? Well, for me it was not enough. For a more personal edge to the kit I decided to add Thoma skirts! Not the massive 5mm plates you frequently see on late Panzer IV tanks and its derivatives, rather the mesh type – lighter, less material-consuming, and a very special detail.

 

These were scratched. There are PE sets available, but that was too expensive and I was not certain if such items would fit in shape and size? So I made a cardboard template for the flanks and built a pair of skirts from styrene strips and a fine PET mesh that I had salvaged from a wallet long time ago.

 

The stuff is hard to glue onto something, so the styrene frame had to carry the mesh parts – and it works! The attachments to the hull were also scratched from styrene.

The Thoma shields add more width to the flat tank, but I think that they set the kit even more apart than just the borrowed IS-3 hull?

  

Painting and markings:

Hmmm, not totally happy with the finish. This was supposed to become a simple Hinterhalt (Ambush) paint scheme in Dark Yellow, Olive Green and Red Brown, but I did so much weathering that not much from the scheme can be recognized…

 

Painting was straightforward, though – I used Humbrol 94 and 173 as well as Modelmaster’s RAL 6003 as basic colors. The scheme’s benchmark is the official Tiger B scheme.

 

The basic colors received mottles in green on the yellow and yellow on the green and brown, and then the thing was thoroughly weathered with a black ink wash, dry-brushing, some aquarelle paint to simulate dust, and finally some pigments that simulate mud.

 

The tracks are made from soft vinyl, and also received a paint treatment in order to get rid of that shiny vinyl look: at first, with a mix of black and silver, which was immediately wiped off again, and later with a second, similar turn with silver and dark brown.

 

The mud was added just before the whole running gear was mounted as one of the final assembly stages, and final retouches were made with acrylic umbra paint.

 

Alas, I think I overdid it – much of the formidable and very attractive paint scheme was lost, even though the yucky, brownish finish now also works fine and looks like rough duty?

  

So, an experiment with good and bad results. Certainly not the last whif tank (at least one more on the agenda), and after so many aircraft a new kind of challenge. ^^

A building at the corner of Main and South Streets in Beacon, NY that's seen some modifications over the years.

Svendborg, Denmark June 27th 1974

The Father Murphy AC 5 Mile Road Race, Fun Run, and Walk was held in Kildalkey, Trim, Co. Meath, Ireland on Easter Sunday 31st March 2013 at 12 noon.

This is the third successive year when the race has been staged in Kildalkey with races previous to 2011 held in the neighbouring parish village of Ballivor. The routing is a modification on the two previous years. This race combined an open 5 mile race and the annual Meath 5 mile road race championship. Traditionally, this race was held on St. Patrick's Day with the venues moving from Athboy, to Ballivor, to the current location of Kildalkey. This was it's first year having an Easter Sunday fixture.

 

The very cold weather of late did not deter over 200 runners, joggers, and walkers participating in the event. There were some great post-race refreshments available for competitors in the Kildalkey Community Center afterwards. Well done to everyone involved - from the members of Fr. Murphy AC, to the neighbouring clubs in Co. Meath - all of whom helped to continue to fine tradition that this race has built up over the past number of years. Our set of photographs are mostly from the finish area of the race. Fr. Murphy AC was formed in 1970 from the amalgamation of several smaller local clubs and now offers some very fine facilities to the people of this part of Co. Meath.

 

The chip timing was provided by Precision Timing [www.precisiontiming.net/result/racetimer]

 

Some links, related to this race, which you might find useful:

 

Father Murphy AC Facebook page: www.facebook.com/pages/Fr-Murphy-AC/138747586197860

MapMyRun Mapping of the Race Route (2013 race route): www.mapmyrun.com/routes/view/181825380

RACE Start line area on Google Street View: goo.gl/maps/Wm4Dp

RACE Finish line area on Google Street View: goo.gl/maps/HIwrA

 

Our Flickr set of photographs from the Father Murphy AC 5 Mile Road Race 2012: www.flickr.com/photos/peterm7/sets/72157629604523577/

Our Flickr set of photographs from the Father Murphy AC 5 Mile Road Race 2011: www.flickr.com/photos/peterm7/sets/72157626286467928/

Our Flickr set of photographs from the Father Murphy AC 5 Mile Road Race 2010: www.flickr.com/photos/peterm7/sets/72157623514578607/

 

Race Results: Precision Timing: www.precisaiontiming.net/result/racetimer

 

Boards.ie Athletics Discussion Thread on the Race. www.boards.ie/vbulletin/showthread.php?t=2056889085

 

Please note: that we cannot be responsible for the content of any external links (outside of ourown Flickr account) as we have no control over them. Links are provided for your information only. Responsibility lies solely with the operators of those websites.

    

How can I get a full resolution copy of these photographs?

 

All of the photographs here on this Flickr set have a visible watermark embedded in them. All of the photographs posted here on this Flickr set are available, free, at no cost, at full resolution WITHOUT watermark. We take these photographs as a hobby and as a contribution to the running community in Ireland. We do not know of any other photographers who operate such a policy. Our only "cost" is our request that if you are using these images: (1) on social media sites such as Facebook, Tumblr, Pinterest, Twitter,LinkedIn, Google+, Google Orkut etc or (2) other websites, web multimedia, commercial/promotional material that you provide a link back to our Flickr page to attribute us. This also means the use of these images for Facebook profile pictures. In these cases please make a wall post with a link to our Flickr page. If you do not know how this should be done for Facebook or other media please email us and we will be happy to help suggest how to link to us.

 

Please email petermooney78 AT gmail DOT com with the links to the photographs you would like to obtain a full resolution copy of. We also ask race organisers, media, etc to ask for permission before use of our images for flyers, posters, etc. We reserve the right to refuse a request.

 

In summary please remember - all we ask is for you to link back to our Flickr set or Flickr pages. We are not posting photographs to Flickr for commercial reasons. If you really like what we do please spread the link around, send us an email, leave a comment beside the photographs, send us a Flickr email, etc.

 

I ran the race - but my photograph doesn't appear here in your Flickr set!

 

As mentioned above we take these photographs as a hobby and as a voluntary contribution to the running community in Ireland. Very often we have actually ran in the same race and then switched to photographer mode after we finished the race. Consequently, we have no obligations to capture a photograph of every participant in the race. However, we do try our very best to capture as many participants as possible. But this is sometimes not possible for a variety of reasons:

 

You were hidden behind another participant as you passed our camera

Weather or lighting conditions meant that we had some photographs with blurry content which we did not upload to our Flickr set

There were too many people - some races attract thousands of participants and as amateur photographs we cannot hope to capture photographs of everyone

We simply missed you - sorry about that - we did our best!

  

You can email us petermooney78 AT gmail DOT com to enquire if we have a photograph of you which didn't make the final Flickr selection for the race. But we cannot promise that there will be photograph there. As alternatives we advise you to contact the race organisers to enquire if there were (1) other photographs taking photographs at the race event or if (2) there were professional commercial sports photographers taking photographs which might have some photographs of you available for purchase. You might find some links for further information above.

 

If you want to contribute something for these images?

We do not charge for these images. We take these photographs as our contribution to the running community in Ireland. If you feel that the image(s) you request are good enough that you would ordinarily pay for their purchase we would suggest that you can provide a donation to any of the great charities in Ireland who do work for Cancer Care or Cancer Research in Ireland.

 

Don't like your photograph here?

That's OK! We understand!

 

If, for any reason, you are not happy or comfortable with your picture appearing here in this photoset on Flickr then please email us at petermooney78 AT gmail DOT com and we will remove it as soon as possible.

 

Another Matchbox Series No4 Dodge K Series Stake Bed Truck Modification. 1966 to 1968 - 1-75 Series. I didn't show it but the body has been painted a silver metallic that is actually a satin finish. I really wanted it gloss but I like this color for some reason. I used the color to restore my 65 Rambler dealer promo. My wife walked over with a box of the kids old 90's Matchbox and Hot Wheels cars that are pretty rough and she said maybe there are some good parts in here and there was this yellow truck box with all of the old cars. Kind of a silly side graphics but I was thinking maybe better than the stake bed.

Not sure why I didn't make that center support right from the get go...

 

www.44bikes.com

HH-60 Flir Upgrade

 

/ Flir Upgrade

 

/ Photo by KAI (2006)

한국항공우주산업

+++ DISCLAIMER +++

Nothing you see here is real, even though the conversion or the presented background story might be based historical facts. BEWARE!

 

Some background:

The G.91Y was an increased-performance version of the Fiat G.91 funded by the Italian government. Based on the G.91T two-seat trainer variant, the single Bristol Orpheus turbojet engine of this aircraft was replaced by two afterburning General Electric J85 turbojets which increased thrust by 60% over the single-engine variant. Structural modifications to reduce airframe weight increased performance further and an additional fuel tank occupying the space of the G.91T's rear seat provided extra range. Combat manoeuvrability was improved with the addition of automatic leading edge slats. The avionics equipment of the G.91Y was considerably upgraded with many of the American, British and Canadian systems being license-manufactured in Italy.

 

Flight testing of three pre-production aircraft was successful, with one aircraft reaching a maximum speed of Mach 0.98. Airframe buffeting was noted and was rectified in production aircraft by raising the position of the tailplane slightly.

An initial order of 55 aircraft for the Italian Air Force was completed by Fiat in March 1971, by which time the company had changed its name to Aeritalia (from 1969, when Fiat aviazione joined the Aerfer). The order was increased to 75 aircraft with 67 eventually being delivered. In fact, the development of the new G.91Y was quite long, and the first order was for about 20 pre-series examples that followed the two prototypes. The first pre-series 'Yankee' (the nickname of the new aircraft) flew in July 1968.

 

AMI (Italian Air Force) placed orders for two batches, 35 fighters followed by another 20, later cut to ten. The last one was delivered around mid 1976, so the total was two prototypes, 20 pre-series and 45 series aircraft. No immediate export success followed, though, and the Italian G.91Ys’ service lasted until the early '90s as attack/recce machines, both over ground and sea, until the AMX replaced them until 1994.

 

However, upon retirement some G.91Ys were still in good condition and the airframes had still some considerable flight hours left, so that about thirty revamped aircraft were put up for sale from 1992 onwards. At the same time, Poland was undergoing a dramatic political change. After the dissolution of the Soviet Union the Eastern European country immediately turned its political attention westward, including the prospects of joining NATO. The withdrawal of Russian forces based in Poland and partly obsolete military equipment of the Polish forces themselves led to a procurement process from 1991 onwards, which, among others, included a replacement for the Polish MiG-17 (domestic Lim-5, Lim-6 and Lim-6bis types), which had been operated by both Polish air force and navy since the late Sixties, primarily as fighter bombers in their late career, but also for reconnaissance tasks.

 

The G.91Y appeared, even though a vintage design, to be a suitable replacement option, since its performance envelope and the equipment outfit with three cameras in the nose made it a perfect package – and the price tag was not big, either. Especially the Polish Navy showed much interest, and after 10 months of negotiations Poland eventually bought 22 G.91Y from Italy, plus five G.91T two-seaters for conversion training, which were delivered between June 1993 and April 1994.

 

For the new operator the machines only underwent minor modifications. The biggest change was the addition of wirings and avionics for typical Polish Air Force ordnance, like indigenous MARS-2 pods for 16 unguided 57mm S-5 missiles, iron bombs of Russian origin of up to 500 kg (1.100 lb) caliber, SUU-23-2 gun pods as well as R-3 and R-60 missiles (which were very similar to the Western AIM-9 Sidewinder and actually date back to re-engineered specimen obtained by the USSR during the Korea war!). All machines were concentrated at Gdynia-Babie Doły in a newly founded, dedicated fighter bomber of the 1 Naval Aviation Squadron, which also operated MiG-21 fighters and PZL Iskra trainers. The Polish G.91Ys, nicknamed “Polski Fiat” by their crews (due to their compact size and overall simplicity, in reminiscence of the very popular, locally license-built Fiat 126), not only replaced the vintage MiG-17 types and some Polish Navy MiG-21 fighters, but also the handful of MiG-15UTI trainer veterans which were still used by the Polish Navy for observation duties over the Baltic Sea.

 

When Poland joined NATO on 12 March 1999, the G.91Ys (18 were still in service, plus all five trainers) received another major overhaul, a new low-visibility paint scheme, and they were updated with avionics that ensured inter-operability with other NATO forces, e .g. a GPS positioning sensor in a small, dorsal hump fairing. In 2006, when deliveries of 48 F-16C/D fighters to Poland started, the G.91Ys were to be retired within 12 months. But problems with the F-16s’ operability kept the G.91Y fleet active until 2011, when all aircraft were grounded and quickly scrapped.

  

General characteristics:

Crew: one

Length: 11.67 m (38 ft 3.5 in)

Wingspan: 9.01 m (29 ft 6.5 in)

Height: 4.43 m (14 ft 6.3 in)

Wing area: 18.13 m² (195.149 ft²)

Empty weight: 3,900 kg (8,598 lb)

Loaded weight: 7,800 kg (17,196 lb)

Max. takeoff weight: 8,700 kg (19,180 lb)

 

Powerplant:

2× General Electric J85-GE-13A turbojets, 18.15 kN (4,080 lbf) each

 

Performance:

Maximum speed: 1,110 km/h (600 kn, 690 mph, Mach 0.95) at 10,000 m (33,000 ft)

Range: 1,150 km (621 nmi, 715 mi)

Max. ferry range with drop tanks: 3,400 km (2,110 mls)

Service ceiling: 12,500 m (41,000 ft)

Rate of climb: 86.36 m/s (17,000 ft/min)

Wing loading: 480 kg/m² (98.3 lb/ft² (maximum)

Thrust/weight: 0.47 at maximum loading

 

Armament:

2× 30 mm (1.18 in) DEFA cannons with 120 RPG

4× under-wing pylon stations with a capacity of 1,814 kg (4,000 lb)

  

The kit and its assembly:

This whiffy Yankee Gina was inspired by a profile that had popped up during WWW picture search a while ago. Tracking it back, I found it to be artwork created and posted at DeviantArt by user “Jeremak-J”, depicting a G.91Y in polish markings and sporting a two-tone grey camouflage with light blue undersides and a medium waterline. I found the idea bizarre, but attractive, and, after some research, I found a small historic slot that might have made this “combo” possible.

 

When I recently delved through my (growing…) kit pile I came across a Matchbox G.91Y in a squashed box and with a cracked canopy – and decided to use that kit for a personal Polish variant.

The Matchbox G.91Y bears light and shadow galore. While it is IIRC the only IP kit of this aircraft, it comes with some problem areas. The fit of any major kit component is mediocre and the cockpit tub with an integral seat-thing is …unique. But the overall shape is IMHO quite good – a typical, simple Matchbox kit with a mix of (very fine) raised and engraved panel lines.

 

The OOB canopy could not be saved, but I was lucky to find a replacement part in the spares box – probably left over from the first G.91Y I built in the early Eighties. While the donor part had to be stripped from paint and was quite yellowed from age, it saved the kit.

 

It was built almost OOB, since major changes would not make sense in the context of my background story of a cheap 2nd hand purchase for an air force on a lean budget. I just added some details to the cockpit and changed the ordnance, using missile pods and iron bombs of Soviet origin (from a Kangnam/Revell Yak-38).

The exhausts were drilled open, because OOB these are just blank covers, only 0.5 mm deep! Inside, some afterburners were simulated (actually main wheels from an Arii 1:100 VF-1).

The flaps were lowered and extended, which is easy to realize on this kit.

The clumsy, molded guns were cut away, to be later replaced with free-standing, hollow steel needles.

In order to add some more exterior detail I also scratched the thin protector frames around the nozzles with thin wire.

Since the replacement canopy looked quite old and brittle, I did not dare cutting the clear part in two, so that the cockpit remained closed, despite the effort put into the interior.

A personal extra is the pair of chaff/flare dispensers on the rear fuselage, reminiscent of Su-22 installations.

  

Painting and markings:

The inspiring profile was nice, but I found it to be a bit fishy. The depicted tactical code format would IMHO not be plausible for the aircraft’s intended era, and roundels on the fuselage flanks would also long have gone in the Nineties. Therefore, I rather looked at real world benchmarks from the appropriate time frame for my Polish Gina’s livery, even though I wanted to stay true to the artist’s original concept, too.

 

One direction to add more plausibility was the scheme that Polish Su-22 fighter bombers received during their MLU, changing the typical tactical camouflage in up to four hues of green and brown into a much more subdued two tone grey livery with lighter, bluish-grey undersides, combined with toned-down markings like tactical codes in white outlines only. Some late MiG-21s also received this type of livery, and at least one Polish Fishbed instructional airframe received white low-viz national insignia.

 

For the paint scheme itself I used the MiG-21 pattern as benchmark (found in the Planes & Pilots MiG-21 book) and adapted it to the G.91Y as good as possible. The tones were a little difficult to define – some painting instructions recommend FS 36118 (US Gunship Grey) for the dark upper grey tone, but this is IMHO much too murky. Esp. on the Su-22s, the two upper greys show only little contrast, and the lower grey does not stand out much against the upper tones, either. On the other side, I found a picture of a real-life MiG-21U trainer in the new grey scheme, and the contrast between the grey on the upper surfaces appeared much stronger, with the light grey even having a brownish hue. Hmpf.

 

As a compromise I settled for FS 36173 (F-15E Dark Grey) and 36414 (Flint Grey). For the undersides I went for FS 35414 (Blue Green), which comes close to the typical Soviet underside blue, but it is brighter.

After basic painting, the kit received a light black ink wash and subtle post-shading, mostly in order to emphasize single panels, less for a true weathering effect.

The cockpit was painted in Dark Gull Grey (Humbrol 140), with a light blue dashboard and a black ejection seat. The OOB pilot was used and received an olive drab suit with a light grey helmet, modern and toned down like the aircraft itself. The landing gear as well as the air intake interior were painted in different shades of aluminum.

 

The decals were, as so often, puzzled together from various sources. The interesting, white-only Polish roundels come from a Mistercraft MiG-21. I also added them to the upper wing surfaces – this is AFAIK not correct, but without them I found the model to look rather bleak. Under the wings, full color insignia were used, though. The English language “Navy” markings on the fuselage might appear odd, but late MiG-21s in Polish Navy service actually had this operator designation added to their spines!

 

The typical, tactical four-digit code consists of markings for Italian Tornados, taken from two different Italeri sheets. The squadron emblem on the fin came from a Mistercraft Su-22, IIRC.

Most stencils were taken from the OOB sheet, some of them were replaced with white alternatives, though, in order to keep a consistent overall low-viz look.

 

Finally the kit was sealed with matt acrylic varnish.

  

An interesting result. Even though this Polish Gina is purely fictional, the model looks surprisingly convincing, and the grey low-viz livery actually suits the G.91Y well.

Leica M10

Leica SUMMILUX-M 50/1.4 ASPH

From the moment I took this guy's face off, his weird brain elastic mechanism made me nervous. I wanted to tighten his strings but I'm supposed to trust a stupid brain thing??? What if the tension snaps the brain in half? Or breaks the headback? (I mean, the headback already has "cracks" in it and everything!) I couldn't really find any evidence that it was doomed (just people wondering how to use it), but still, I don't trust it.

 

So I used an exacto knife to carve little notches on the neck hole, and now it's strung with a keyring. Actually I think that ring came from another doll. But anyway, I trust this a lot more!

 

Just posting it up for anyone else to use as a reference if they want to try it :D

This App is awesome. Only the third app I've ever purchased

=]

Toposa tribe woman with scarified face, Omo valley, Kangate, Ethiopia , Camera: ILCE-7RM2 , f2.8 , 1/200 , 34.0 mm , ISO 1600 , © Eric Lafforgue www.ericlafforgue.com

This photo is courtesy of the late John Garnham, a British Columbia collector. The right-side front and rear prism plate modifications are shown as well as both objective decorator cap/cel housing modifications.

Easy stuff to do to tighten up your iOtpron SmartEQ or Pro and make it enjoyable to use.

Easy stuff to do to tighten up your iOtpron SmartEQ or Pro and make it enjoyable to use.

Collaboration with 'Infected by Design"